MICHAEL POLLAK
CURRICULUM VITAE
Home Address
4889 Mira Rd.
Montreal, Quebec, Canada
H3W 2B7
Tel: (514) 486-7412
Office Address
Department of Oncology
Jewish General Hospital / McGill University
3755 Côte Ste-Catherine Rd.
Montreal, Quebec, Canada
H3T 1E2
Tel.: (514) 340-8222 ext. 5530 (office)
(514) 340-8222 ext. 5527 (secretary)
(514) 340-8222 ext. 4139 (lab)
(514) 340-8248 (clinic)
Fax: (514) 340-8600 (office)
(514) 340-8716 (lab)
E-mail: michael.pollak@mcgill.ca
Revised May 2011
Michael Pollak, MD
HIGHLIGHTS OF CV

Experienced clinician-scientist certified in Internal Medicine and Medical Oncology.

Active research program, with > $12 million peer-reviewed funding awarded for laboratory research
despite an appointment that has included substantial time in clinical practice.

Leadership roles in national and international research networks

Teaching activities at undergraduate and graduate levels highly rated.

Extensive clinical trial and translational research experience.

Experience in managing private sector - academic - government collaborations in oncology.
2
PERSONAL DATA
Date of Birth
August 8, 1952
Place of Birth
Montreal, Quebec, Canada
Marital Status
Married with three children
Languages
English, French
EDUCATION
UNDERGRADUATE:
1970
1970
1973
1973
“Cum Laude” Graduate of Selwyn House School, Montreal, Quebec
“Cum Laude” Certificate, Ecole de Français, Montreux, Switzerland
University Entrance Scholarship Diplome d'Etudes de College (Science)
Dip. Collegial Studies, McGill University, Biology and Computer Science
MEDICAL:
1977
M.D. McGill University
POST-GRADUATE MEDICAL TRAINING:
1977-78
Rotating Internship
St. Michael’s Hospital, University of Toronto
1979-80
Internal Medicine Residency
St. Michael’s Hospital, University of Toronto
1980-81
Internal Medicine Residency
Toronto General Hospital, University of Toronto
1981-83
Internal Medicine and Medical Oncology Residencies
Princess Margaret Hospital and associated teaching units, University of Toronto
EXTRA-CURRICULAR ACTIVITIES AS RESIDENT:
1980-81
President, House-staff Association, Toronto General Hospital and House-staff Representative to
TGH Medical Advisory Board
1980-82
Part-time consultative position with IBM Canada Ltd. as “Health Industry Specialist” (with approval
of Dept. of Medicine, University of Toronto)
POST-RESIDENCY RESEARCH FELLOWSHIP AND ACTIVITIES:
1983-85
Terry Fox Fellowship awarded by National Cancer Institute of Canada and Ontario Cancer Institute
(laboratory of Dr. Ron Buick)
3
1983-85
1984-85
Associate Physician, Department of Medicine (Division of Hematology/Oncology), Toronto General
Hospital, and Lecturer, Department of Medicine, University of Toronto
Part-time Clinical Staff Appointment Department of Medicine, Woman's College Hospital, Toronto
PROFESSIONAL CERTIFICATIONS
1978
1978
1978
1978
1982
1982
1984
1985
1985
1985
1987
1994
Medical Council of Canada Certification
National Board of Medical Examiners, USA Certification
General License for Medical Practice, Ontario
General License for Medical Practice, British Columbia
General License for Medical Practice, California
FRCPC Specialty Certificate in Internal Medicine (Canada)
Elected to membership of ASCO (American Society of Clinical Oncology)
General License for Medical Practice, Quebec
Elected to membership of AACR (American Association for Cancer Research)
Certification as Specialist (Internal Medicine), Quebec
FRCPC Specialty Certificate in Medical Oncology (Canada)
Certification as Specialist (Medical Oncology), Quebec (This Specialty first recognized by
Corporation Professionelle des Medecins in 1994.)
APPOINTMENTS
UNIVERSITY:
1984
19851985-90
1985-90
199019901991-96
1993-99
19951997199719971998199920022002-
Lecturer, Department of Medicine, University of Toronto
Project Director, Lady Davis Institute for Medical Research
Assistant Professor, Department of Medicine, McGill University
Assistant Professor, Cancer Center, McGill University
Associate member, McGill AIDS Center
Member, Division of Experimental Medicine, Department of Medicine, McGill University
Associate Professor, Departments of Oncology and Medicine, McGill University
Riesman Clinician-Scientist, Department of Oncology, Jewish General Hospital and McGill
University (replaced by Research Chair, see below)
“Chercheur-boursier clinicien” award from Fonds de la Recherche en santé du Québec (FRSQ)
Board of Directors, Center for Translational Research in Oncology, McGill University
Scientific Advisory Board, Center for Translational Research in Oncology, McGill University
Professor (tenured), Departments of Medicine and Oncology, McGill University
“Chercheur-boursier clinicien” (senior) award from FRSQ
Alexander-Goldfarb Research Chair in Medical Oncology, McGill University
“Chercheurs-Nationaux” award from FRSQ (ranked first in this competition)
Director, Cancer Prevention Program, Department of Oncology, McGill University
HOSPITAL:
1978
General Practice Locum, Windermere District Hospital, Invermere, British Columbia (May to
September)
4
1981-84
Emergency Room Privileges, J.O. Ruddy General Hospital, Whitby, Ontario, and part-time staff,
Ajax-Pickering Hospital, Ajax, Ontario (weekend work during residency training)
1984
Part-time Staff, Division of Oncology, Woman's College Hospital Toronto (in conjunction with Terry
Fox Fellowship at Ontario Cancer Institute)
1985-
Staff Physician, Department of Internal Medicine and Oncology, Jewish General Hospital, with
following clinical responsibilities:
1985-89
Oncology Consultation Service - : 6 months/year
1989Oncology Consultation Service - : 4 months/year
1986-88
General Medicine Service - : 2 months/year
1985Oncology Outpatient Service - : approx. 40 patients/week
1985Oncology Inpatient Service - : approx. 2 admissions/week
1994-99
Co-director, Tumor Board, Jewish General Hospital
1997-
Member, Department of Endocrinology, Jewish General Hospital
1997-
Director, Cancer Prevention Research Unit, Department of Oncology
AWARDS
1973
1983
1993
1995
1997
1998
1999
1999
2002
University entrance scholarship, McGill
Terry Fox Fellowship Award, Ontario Cancer Institute
Riesman Career Scientist Award, Department of Oncology McGill University and Jewish General
Hospital
FRSQ Clinician Scientist award
Promotion to Full Professor (tenured), McGill University
FRSQ Senior Clinician Scientist award
McGill University Scientist of the year–1998, “McGill Reporter”
Alexander-Goldfarb Chair in Medical Oncology, McGill University
FRSQ National Scientist award (ranked first in this competition)
TEACHING
MEDICAL STUDENTS AND RESIDENTS:
1985-
Supervision and teaching of Clinical Fellows, residents, interns, and medical students attending my
outpatient clinic (average 8 months/year)
1986-99
Supervision and teaching of Clinical Fellows, residents, interns, and medical students on teaching
ward with respect to Medical Oncology (4 months/year)
1986-87
Clinical Skills Examiner–3rd year medical students
1986-88
Supervision and teaching of on General Medical Ward with respect to General Internal Medicine.
(2 months/year)
5
1990
Supervision of S Malaab, Canadian Association of Medical Oncology (CAMO) Award for best
trainee presentation at Royal College Annual Meeting, Toronto
1994
Supervision of V Thanos, pre-medical student summer research project
1994
Supervision of A Jacobson, medical student summer research project
1994-95
Thesis advisor, Catherine Phelan, Visiting PhD Student, Karolinska Institute Ph.D. granted 1997
1995
Supervision of J Rosenblatt, medical student summer research project
1995
Education Committee, Department of Oncology
1995
Undergraduate Medical Education: small group teaching in Biology of Oncology
1996
Examiner, Radiation therapy residents
1996
Participant, Faculty Teaching Skills Workshop
1997
Whole class teaching for medical students, Oncology Therapeutics
1997
Small group teaching, second year medical students
1999
Oncology Service Teaching Rounds, Dept. of Medicine, Jewish General Hospital
2002-
Small group teaching for medical students, Cancer Prevention
2002-
Whole class undergrad medical student lectures in cancer prevention.
2002-
Dept of Oncology ‘clinical science for basic scientists’ lecture series
Ph.D. AND POST-DOCTORAL STUDENTS:
1992-97
Supervision of post-doctoral fellow H Hung
1995-99
Supervision of PhD student Tara Nickerson
1997-2004
Supervision of PhD student Yuhong Lu
1999-2006
Supervision of PhD student Randy Levitt
1999-2002
Supervision of post-doctoral fellow Xiaolin Zi
1999-
Supervision of post-doctoral fellow Marie-José Blouin
2000-06
Supervision of post-doctoral fellow Anne Camirand
2003-
Supervision of post-doctoral fellow Mahvash Zakikhani
2006-07
Supervision of post-doctoral fellow Matthew Cunningham
6
2006-
Supervision of PhD student Matei Mireuta
2006-2011
Supervision of PhD student Carolyn Algire
2007-09
Supervision of master student Carly Dool
2007-09
Supervision of visiting research fellow Esther Piura (Tel Aviv University)
2008-09
Supervision of post-doctoral fellow Takamitsu Inoue
2009-
Supervision of master student Haider Mashhedi
2010-
Supervision of master student Shiva Javeshghani
2010-
Supervision of post-doctoral fellow Henning Hvid
Ph.D. THESIS AND COMPREHENSIVE EXAM COMMITTEES
1990
H Wang (Division of Surgical Research)
1993
R Schecter (Department of Experimental Medicine)
1997
N Giannoukakis (Department of Experimental Medicine)
1998
L Long (Department of Experimental Surgery)
1999
L Zi (Department of Pharmacology)
2002
C Hamelin (Department of Pediatrics), Université de Montreal
OTHER CONTRIBUTIONS
COLLABORATIVE CLINICAL TRIAL GROUP ACTIVITIES
NCI (USA)
Cancer Therapy Evaluation Program
Investigator number 14676
NSABP
(National Surgical Adjuvant Breast and Bowel Project)
Participant, 1985Appointed to Biological Markers Committee, 1987
B29 Tamoxifen octreotide adjuvant breast cancer trial design committee, 1995-6
Appointed to breast cancer management committee, 1997
NCIC
(National Cancer Institute of Canada)
Participant, 1985Appointed to breast site committee, 1995
Principal Investigator, MA14 adjuvant breast cancer trial 19967
Translational Science Leader, colorectal committee, 2008 –
Breast IND group, 2009 CALGB
(Cancer and Leukemia Group B)
Participant, 1995-97
SWOG
(South West Oncology Group)
Consultant, regarding translational research component of the Prostate Cancer
Prevention Trial, 2001-
In my clinical practice, I enroll patients in clinical trials coordinated by the above groups as well as others
arranged locally.
MANUSCRIPT REVIEW FOR SCHOLARLY PUBLICATIONS
Journal of Clinical Investigation
Cancer
Cancer Research
Gene
Clinical Cancer Research
Cell Growth and Differentiation
Oncology Research
Proceedings of the Society for Experimental Biology and Medicine
Peptides
American Journal of Obstetrics and Gynecology
Journal of Clinical Endocrinology and Metabolism
Endocrinology
International Journal of Cancer
Biotechniques
Journal of Molecular Endocrinology
Journal of the National Cancer Institute
Gynecologic Oncology
Lancet
GRANT PANELS
1990
Cancer Research Society, Montreal, Medical Advisory Board
1989-90
National Cancer Institute of Canada, Review Panel J, Biology/endocrinology
1994
MRC Canada, Chairman, Site Review panel for a $1.2 million research program
1994
US Army Breast Cancer Program: member, Cancer Biology grant review panel, Receptor biology
1996
US Army Breast Cancer Program: member, Cancer Endocrinology review panel
1996-98
National Cancer Institute of Canada, Review Panel J, Molecular epidemiological and clinical
correlative studies
1998
MRC Canada, Chairman of a site review panel for a multimillion-dollar research program
8
(declined)
1998
NCIC, Member of a site review panel for a multimillion dollar research program
1997-99
Israel Cancer Research Fund
2002-
NIH/ NCI grant review study sections (cancer prevention, epidemiology of cancer), invited
member
2005-
Israel Cancer Research Fund
2005-
Prostate Cancer Research Foundation of Canada
2005-
Site review responsibilities in Ireland and Sweden
AD HOC GRANT REVIEWS
I have been asked to review grant applications submitted to:
Cancer Research Society
National Cancer Institute of Canada
MRC Canada and CIHR
FRSQ
Manitoba Health Research Council
NIH/NCI (USA)
New South Wales (Australia) Cancer Society
ADMINISTRATIVE RESPONSIBILITIES
National and International
1. Scientific Congress Organization
1992
Program Committee, International Somatostatin Symposium, Monte Carlo
1993
Program Committee, National Breast Cancer Forum, Montreal, Quebec
1995
Program Committee, International Somatostatin Symposium, Sorrento, Italy
1999
Coordinator and Program Committee, First International Workshop on growth hormone, insulinlike growth factors, and neoplasia, Boston, October
1999
Chair, Clinical Endocrinology Section, American Association for Cancer Research (AACR) meeting,
San Francisco, April
2002
Chair, Scientific Committee, Fondation Chagnon International Symposium on Cancer Prevention,
Montreal, November
2006
Chair, Scientific Committee, Workshop on “Milk consumption, hormones, and human health”,
Harvard University, Boston, October
9
2006
Program Committee, St. Gallen International Cancer Prevention Symposium,
St. Gallen, Switzerland, February
2008
Program Committee, St. Gallen International Cancer Prevention Symposium,
St. Gallen, Switzerland, February
2008
Organizing Committee, International symposium on insulin-like growth factors, Genoa, Italy
October, 2008
2. Multicenter Clinical Trial Organization
1995-
Principal Investigator, NCIC MA-14 Project. This clinical trial involves a partnership between NCIC
Clinical Trials Group, CIHR, and NOVARTIS. It established one of the first major clinical trialassociated biobanks (DNA, serum, tissue) linked to a patient outcome database.
3. Miscellaneous
1998
2002-07
2008-
Canadian Breast Cancer Research Initiative, invited participant in programmatic review.
Scientific Advisory Committee, Canadian Breast Cancer Research Alliance
Editorial Board, Cancer Prevention Research (AACR Journal)
University
1. McGill Cancer Center—Institutional Review Board (IRB) liaison regarding all consent forms for oncology
clinical trials at McGill (1986-1987)
2. Chairman, Endocrine—Biologicals Section of Clinical Trials Group, Department of Oncology (1992- 1995)
In this capacity, I arranged for the Department to participate in various clinical trials in collaboration with
pharmaceutical companies. I also have established priorities for clinical trials proposed. All trials I have
proposed and coordinated have met accrual targets and generated income for the University in excess of
expenses.
3. Director, Division of Cancer Prevention, Department of Oncology. (2002- )
Hospital
1. Clinical Trials Administration in Oncology at JGH
1992-2000
Recruiting of staff. I identified and recommended individuals for data manager - clinical trial nurse
teams.
1992-2000
Arranging of laboratory support for clinical trials. I arranged for special handling and processing of
blood and tissue samples obtained in connection with clinical trials run in the Oncology Clinic. This
enabled us to participate in trials requiring such samples.
2. Co-Chair, Tumor Board, JGH, 1994This function involves both teaching and service functions. New patients are discussed by a multidisciplinary
audience including members of various surgical specialties, radiotherapists, and medical oncologists. Nurses,
10
pharmacists, data managers, residents, and students also participate. Treatment options are reviewed,
particularly with respect to ongoing clinical trials. The Chair helps select cases, leads the discussion, and
documents the recommendations of the Tumor Board.
3. Member, Search Committee, Chief, JGH, Dept. of Oncology, 1986
4. Supportive Care Committee, 1986-1994
5. JGH Computerized Patient Information Committee, 1986
6. Chairman, Research Computing Committee, Lady Davis Institute, 20057. Director, Cancer Prevention Research Unit, Jewish General Hospital, 1997In this capacity, I act to co-ordinate cancer prevention research activities. We have established a group of
laboratory and clinical scientists working in this area. I have recruited a clinician-scientist in the field of cancer
genetics to run a clinic for individuals concerned about inherited or acquired cancer risk. In addition to
research activities, an information office provides services to the public and to referred clients concerning
cancer prevention.
EXAMPLES OF CONTRIBUTIONS TO PUBLIC MEDIA
“Patience needed on cancer cure”, Montreal Gazette, page B3 [op-ed], May 29, 1998
Cancer Research Segment for National Network Distribution (Canadian Broadcasting Corporation), 1998
“McGill Reporter” survey: McGill researcher most cited in public media, 1998
Top-ranked public lecturer at “Minimed” program of JGH, 2007
EXAMPLE OF PUBLIC SECTOR CONSULTING
Member, Health and Welfare Canada Expert Committee on bovine somatotropin, 1998
EXAMPLES OF PRIVATE SECTOR CONSULTING
AND ACADEMIC COLLABORATIONS
(see RESEARCH section)
MISCELLANEOUS AFFILIATIONS
Member, Canadian Medical Association
Member, Ontario Medical Association
Member, Quebec Medical Association
Fellow, Royal College of Physicians and Surgeons of Canada
Member, College of Physicians of Ontario
Member, Federation of Medical Specialists of Quebec
Member, American Society of Clinical Oncology
Member, American Association for Cancer Research
Member, Canadian Society for Clinical Investigation
Member, Canadian Association of Medical Oncologists
11
Member, Prostate Cancer Research Foundation of Canada
RESEARCH
My research interests concern the role of peptide mitogens in the control of cellular proliferation, and
derangements of these control systems in malignancy. I have experience in laboratory, clinical and populationbased research.
EXTERNAL SALARY SUPPORT
“Chercheur-boursier clinicien” award (FRSQ) 1995 - 2003: $42,042/year
“Chercheurs Nationaux” award (FRSQ) 2003 – 2008: $65,000/year
RESEARCH GRANT SUPPORT
(A) Laboratory work
(* indicates that Michael Pollak is Principal Investigator or Co-Principal Investigator)
$25,000
1989
*Shyamala G, Kalant N, Pollak M. Mechanisms of diet restriction – related reduction of
carcinogen- induced breast cancer in rats. Cancer Research Society of Montreal
$10,000
1989
*Pollak M, Polychronakos C. Support for study evaluating effect of SMS 201-995 on serum IGF-1
levels in cancer patients. Sandoz Canada
$200,000
1989-92
*Pollak M. Role of Somatomedins and EGF in determining the proliferative behavior of human
neoplasms. Cancer Research Society of Montreal
$21,000
1991
*Pollak M. Antiestrogen - Somatostatin synergy in animal models of breast cancer. Canadian
Breast Cancer Foundation
$186,000
1991-93
*Pollak M, Bell R. Somatomedins-relevance to osteosarcoma. National Cancer Institute of Canada
$20,000
1992
*Pollak M. Octreotide preclinical activity in breast cancer. Sandoz, Basle
$50,000
1992
*Pollak M. Central growth factor lab for analysis of sera collected in international phase II
somatostatin clinical trials. Sandoz Research Institute, East Hanover, USA
$130,000
1992-95
*Pollak M. Somatomedins: relationship to endocrine cancer therapies. National Cancer Institute
of Canada
$180,000
1994-97
*Bell R, Pollak M. Somatomedins and osteosarcoma. National Cancer Institute of Canada
$32,000
1995-96
*Pollak M. Use of the “lit” mutation to evaluate the growth-hormone-IGF-I axis as a host factor
influencing neoplastic behavior. MRC
12
$293,625
1995-98
*Pollak M. Tumor suppressor properties of the gene encoding mammary derived growth inhibitor.
$346,700
1995-99
*Pollak M. Insulin-like growth factor I in the pathophysiology in neoplasia. National Cancer
Institute of Canada
$2,928,000
1996-2001
*Pollak M. Translational research regarding antiestrogen-somatostatin therapy. (This budget
includes administration of a multicenter clinical trial and operating funds for associated laboratory
studies.) MRC-PMAC program (administered by Medical Research Council, Canada)
$30,000
1997
*Pollak M. Novel biological source metalloproteinase inhibitors: assay in experimental breast
cancer metastasis. Canadian Breast Cancer Foundation
$149,625
1997-98
*Pollak M. IGFs and Breast Cancer Risk. National Cancer Institute of Canada
$228,873
1997-2000
*Pollak M, Bell B. IGFs and sarcoma. National Cancer Institute of Canada
$162,972
1997-2000
Pritchard K, and others including Pollak M. A national tumor and data bank for patients in NCIC
clinical trials. National Cancer Institute of Canada
$300,698
1997-2000
*Pollak M, Karaplis A. PTHrP in normal breast development. National Cancer Institute of Canada
$110,000
1997-2001
*Pollak M. Contract for collaborative research with Environmental Epidemiology Branch, National
Cancer Institute. USA
$460,000
1997-2001
*Pollak M. Subcontract for endocrine epidemiology in relation to cancer risk. National Cancer
Institute/ Harvard School of Public Health
$135,000
1998-99
*Pollak M, Eyssen G. Serum markers of IGF physiology and colon cancer risk. National Cancer
Institute of Canada
$50,000
1998-99
*Pollak M. Contract research. Sensus Corporation
$240,000
1998-2000
Narod S, Pollak M and others. Prognostic factors for metastatic progression of localized prostate
cancer. National Cancer Institute of Canada
$18,000
1998-2000
*Pollak M. Breast Cancer Prevention Based on Hormonal Factors. National Breast Cancer Fund
$306,000
1998-2001
Klotz L and others including Pollak M. Basic science companion laboratory studies to NCIC CTG
trial PR-7. National Cancer Institute of Canada
~$1,000,000
1998-2006
Pollak M. Subcontracts for laboratory work awarded to MP by Harvard University (Using NIH
funding to Harvard School of Public Health)
13
$65,000
1999-2000
*Pollak M. Contract research. Axys Pharma
$19,672
1999-2000
*Pollak M. Team-building award, Canada Breast Cancer Research Initiative
$80,000
1999-2001
*Pollak M. Contract research. Diagnostic Systems Limited
$216,900
1999-2001
Narod S and others including Pollak M. The role of serum IGF-I levels and androgen receptor
genotype in prostate cancer diagnosis. National Cancer Institute of Canada
$458,016
1999-2002
*Pollak M. Serum markers of IGF physiology and risk of breast, prostate, and colon cancer.
National Cancer Institute of Canada
$20,600
2000-01
*Pollak
*
M. IGFs and cancer risk in the CARET cohort. Subcontract for Dr. M Spitz.
$18,000
2000-01
*Pollak M. IGF physiology in relation to lung cancer risk and prevention. Subcontract for IGF-I
assay work for Dr. M Spitz and collaborators.
$130,000
2000-01
*Pollak M. Subcontract for growth factor assays, US Army/ Physicians’ Health Study
$156,000
2000-01
*Pollak M. Component of NCI (USA) contract N01-CN-95040-46 awarded to Euhus D et al,
University of Texas, Dallas. ‘An exploratory study to identify potential surrogate endpoint
biomarkers that are modulated by tamoxifen vs placebo in women with an increased risk for
breast cancer’
$291,168
2000-02
*Pollak M. Silibinin in prostate cancer chemoprevention and treatment. National Cancer Institute
of Canada
$53,992
2000-02
Pollak M. ATBC cancer risk cohort studies, NIH subcontract from Dr. Albanes
$2,994,444
2000-03
*Pollak M and co-investigators. IGFs and breast cancer: “Streams of Excellence” program award,
Canadian Breast Cancer Research Initiative
$418,120
2000-04
Franco E and others including Pollak M. Biomarkers of cervical cancer. CIHR
~$125,000
2000-04
Ziegler R and others including Pollak M. Biomarker of colon cancer risk in the PLCO cohort.
National Cancer Institute (USA)
$1,500,000
2000-05
Eyssen G, and others including Pollak M. Canadian Cancer Etiology Research Network, NCIC. (Dr.
Pollak leads the “hormonal risk factor” component of the network.)
$3,098,278
2001-07
Bristow R, and others including Pollak M. Canadian Molecular and Micronutrient Prostate Cancer
Research Network
14
$410,000
2003-06
* Pollak M. Silibinin in prostate cancer chemoprevention and treatment. Department of Defense –
U.S. Army
$440,000
2003-06
*Pollak M. Co-targeting of IGF-IR signaling and other tyrosine kinases in breast cancer. The Susan
G. Komen Breast Cancer Foundation.
$49,000
2003-04
*Pollak M, Majeed N. Model development: IGF-I deficiency and prostate cancer. National Cancer
Institute of Canada – Canadian Prostate Cancer Research Initiative
$130,000
2003-05
* Pollak M. Silibinin in prostate cancer chemoprevention and treatment. National Institutes of
Health –National Cancer Institute
~$3,000,000
2003-09
Kaplan R, and others including Pollak M and co-investigators. Epidemiology of IGF and
cardiovascular events. National Institute of Health
~$2,000,000
2003-06
Kristal AR, and others including Pollak M and co-investigators. Cohort Study of Risks for Benign
Prostatic Hyperplasia. National Institute of Health
$141,000
2004-05
Pollak M. Subcontract for laboratory work awarded to MP by John Hopkins University (Using NIH
funding)
$130,000
2004-05
Pollak M. Subcontract for laboratory work awarded to MP by NCI intramural program (USA) (Using
NIH funding)
$58,500
2005-06
* Pollak M. Relationship between hedgehog signaling and IGF physiology in prostate cancer.
(PCRFC)
$2,948,563
2005-09
* Pollak M and co-investigators from University of British Columbia, University of Toronto, Laval
University, and McGill University. IGF and insulin signaling pathways in breast cancer:
“Translation Acceleration Grant” program award. Canadians Breast Cancer Research Alliance.
(MP chairs this multi-center Program.)
~$18,000,000 *Lippman S, and others including Pollak M and co-investigators. Biology of the prostate cancer
2005-09
prevention trial. National Cancer Institute
$50,000.00
2005-09
McTiernan A and others including Pollak M and co-investigators. Glycemic load and obesity effects
on cancer biomarkers. National cancer Institute
$375,000
2007-10
*Pollak M. Dietary factors influencing IGF signaling in prostate cancer – laboratory studies
(ranked # 1 by review panel) NCIC
$88,000
2007
*Pollak M. Mediators of the adverse impact of obesity on risk for high grade prostate cancer.
Prostate Cancer Foundation (Los Angeles)
$1,500,000
2008-11
*Smith MR, and others including Pollak M and co-investigators. Prevention of treatment and
disease-related morbidity during androgen deprivation therapy: a multicenter proposal. Prostate
Cancer Foundation (Los Angeles)
$1,010,000
2008-10
*Pollak M and co-investigators from McGill University. Clinical targeting of IGF-1/Insulin Signaling
via the P13K/AKT/mTOR pathway to treat breast and prostate cancers. Terry Fox Research
15
Institute
$40,000
2009-10
*Pollak M. Influence of Excess Energy Intake on Breast Cancer Behavior. The Weekend to End
Breast Cancer and the Jewish General Hospital Foundation
$30,000
2009
Yehiel Zick and *Pollak M. Insulin and IGF-I signaling in cancer. Weizmann-McGill 2009 partnership
grants
~$500,000
2009-12
*Pollak M and Harvard collaborators. Modifiable dietary determinants of levels of IGF-I, insulin,
and risk of colorectal cancer and lethal prostate cancer. Canadian Cancer Society
$60,000
2009-10
*Pollak M. PTEN loss and energy metabolism in prostate cancer. Prostate Cancer Canada
$10,000
2009
*Pollak M. China – Canada collaboration program, CIHR, seed funds awarded on acceptance of
LOI, to allow preparation of a major application.
~$2,300,000
2009-14
*Aviv A and others, including Pollak M and co-investigators. Leukocyte telomere dynamics,
gender, menopause, insulin resistance and survival. NIH – National Institute on Aging
$650,000
2010-13
*Pollak M. Research concerning insulin-like growth factors and cancer. Pfizer Canada
$400,000
2010-12
*Pollak M. Murine models to study the effects of diabetes and diabetes treatments, including
insulin analogues, on cancer behavior. Novo Nordisk
$195,000
2011-13
*Pollak M. Effects of metformin on colorectal epithelial cell proliferation. Canadian Cancer Society
(B) Clinical Trials
$100,000
1990-93
Principal Investigator for SMS 201-995/CV 205-502 breast cancer trial. Sandoz Canada
$120,000
1993
Principal Investigator for 3 phase II somatostatin trials (colon, ER negative breast, and ER positive
breast) Sandoz Canada
See section
A
Principal Investigator, NCIC octreotide-tamoxifen breast cancer adjuvant trial.
This is a ~800 patient multicenter trial proposed, designed and implemented by Dr. Pollak with
involvement of Sandoz (now Novartis) affiliates in Canada and USA as well as head office in Basle,
National Cancer Institute of Canada, Medical Research Council of Canada, and more than 25
hospitals across Canada. Funding award for translational research component by MRC-PMAC
program (administered by Medical Research Council, Canada), 1996-1999. My lab manages the
translational research component of this study, and conducts assays on serum and neoplastic
tissue from participating patients.
$50,000
1995
Principal Investigator at McGill for Recombinant humanized anti-HER2 antibody therapy in breast
cancer patients with HER2 overexpression. Genentech
$55,000
Principal Investigator at McGill for Randomized double-blind trial to compare efficacy
16
1995
and safety of anastrozole with tamoxifen as first-line therapy for advanced breast cancer in
postmenopausal women. Zeneca Pharma
$30,000
1996
Principal Investigator at McGill for Phase II study of EM-800 in tamoxifen-resistant breast cancer.
CHUL research Center
$60,000
1998
NSABP B29 breast cancer adjuvant trial. Proposed this trial to NSABP, and participated in protocol
design.
$40,000
1998-99
Principal Investigator at McGill for phase II study of MDR modifiers. Vertex Pharmaceuticals
$50,000
1998-99
Principal Investigator at McGill phase III study for EM-800 vs. aromatase inhibitors. Scherring
~$100,000
2004-
Principal Investigator at McGill of LBQ707A-2102 Phase Ib Study. Novartis.
~$80,000
2005-
Co-Principal Investigator at McGill of IGF-I receptor blocking antibody Phase Ib study. Pfizer
~$500,000
2004-09
Fleshner N. (PI), Pollak M and co-investigators.Translation Companion Study to PRP.1 Ontario
Cancer Research Network
$175,000
2007-
Pollak M (PI) et al. A pharmacodynamic study of IGF-I receptor blockade in prostate cancer. Pfizer
Canada 2007
$80,000
2007-
Pollak (PI) Laboratory services contract to process specimens from an international breast cancer
trial. Pfizer Global (USA)
(C) Grants awarded to trainees during or following study in laboratory of Dr. Pollak
Huynh H. Canadian Breast Cancer Foundation Award
Nickerson T. FRSQ Studentship
Huynh H. Cancer Research Society operating grant
Huynh H. US Army Breast Cancer Program
Levitt R. US Army Pre-Doctoral Traineeship
Mireuta M. WEBC Studentship Award
Algire C. MCETC/ FRSQ/ CIHR Studentship Award
Dool C. MCETC/ FRSQ/ CIHR Studentship Award
Mashhedi H. MICRTP Studentship Award
Algire C. CIHR Doctoral Award
$30,000
$12,000
$45,000
~$350,000
~$67,000
$24,000
$24,000
$24,000
$12,000
$35,000
1995-96
1996-97
1996-97
1997-99
2003-05
2007-09
2008-10
2008-10
2010-11
2010-13
EXAMPLES OF ACADEMIC COLLABORATIONS OUTSIDE McGILL
Dr. Wes Beamer, Jackson Laboratory (“lit” mutation)
Dr. Catharina Larsson, Karolinska Institute, Stockholm (MDGI gene)
Dr. Steven Narod, Chair, Breast Cancer Research, University of Toronto (hormonal modifiers of penetrance of
genetic risk factors for cancer)
Dr. Robert Bell, University of Toronto (IGFs and osteosarcoma)
17
Dr. W Willett, Chair, Dept. of Nutrition, Harvard School of Public Health (Nurses’ Health Study: markers of
breast cancer risk)
Dr. R Ziegler, Division of Cancer Genetics and Epidemiology, NCI-NIH, USA (Breast cancer: genetic
polymorphisms underlying hormonal risk factors)
Dr. M Stampfer, Harvard University (risk factors for prostate and colon cancer)
Dr. M Gleave, University of British Columbia (novel molecular target identification for prostate and breast
cancers)
Dr. R Kaplan, Albert Einstein University (IGFs and cardiovascular disease)
Dr. J Brisson, Laval University (hormonal influences on mammographic breast density)
EXAMPLES OF INDUSTRIAL COLLABORATIONS
AND PRIVATE SECTOR CONSULTING
Novartis Research Institute, Basle, Switzerland
Astra Zeneca Pharmaceuticals, Manchester, UK
Diagnostic Systems Limited, Webster, Texas (appointed to Scientific Advisory Board, 1998)
Orion-Farmos, Helsinki, Finland
Ipsen Biotech, Paris, France
Sensus Biotech, Austin, Texas
L.A.B. Pharma Research International, Vaudreuil, Quebec
Cadus Pharmaceuticals, NY
Axys Pharma, San Francisco
Sanofi-Aventis, Paris
Pfizer Global Research, New York
PATENTS
- Bispecific oligonucleotide for the treatment of CNS malignancies (co-inventor, patent owned by University of
British Columbia)
- IGF-I and related analytes in assessing cancer risk (co-inventor, patent licensed to Diagnostic Systems Limited)
PUBLICATIONS
(* indicates first author supervised by Dr. M Pollak; vertical lines indicate key papers)
Peer-reviewed articles (published or in press)
1978-1989
1. Fletcher S, Ratzer G, Pollak M. Computer-based appointment scheduling for ambulatory patients. Meth
Information Med 17: 167-72, 1978.
2. Pollak MN. Computer-aided information management systems in clinical trials. A physician’s perspective.
Comput Programs Biomed 16: 243-51, 1983.
3. Buick RN, Pollak MN. Perspectives on clonogenic tumor cells, stem cells, and oncogenes. Cancer Res 44:
4909-18, 1984.
4. Filmus J, Pollak MN, Cailleau R, Buick RN. MDA-468, a human breast cancer cell line with a high number
of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited
by EGF. Biochem Biophys Res Commun 128: 898-905, 1985.
18
5. Filmus J, Pollak MN, Cairncross JG, Buick RN. Amplified, overexpressed and rearranged epidermal growth
factor receptor gene in a human astrocytoma cell line. Biochem Biophys Res Commun 131: 207-15, 1985.
6. Filmus J, Trent JM, Pollak MN, Buick RN. Epidermal growth factor receptor gene-amplified MDA-468
breast cancer cell line and its nonamplified variants. Mol Cell Biol 7: 251-7, 1987.
7. Pollak MN, Perdue JF, Margolese RG, Baer K, Richard M. Presence of somatomedin receptors on primary
human breast and colon carcinomas. Cancer Lett 38: 223-30, 1987.
8. Pollak MN, Polychronakos C, Yousefi S, Richard M. Characterization of insulin-like growth factor I (IGF-I)
receptors of human breast cancer cells. Biochem Biophys Res Commun 154: 326-31, 1988.
9. *Gonzalez-Vela JL, Panasci L, Black M, Pollak M, Margolese R. Combination chemotherapy with
carboplatinum and bleomycin for advanced and recurrent head and neck cancer: a phase II study. J Surg
Oncol 39: 215-6, 1988.
10. Suissa S, Pollak M, Spitzer WO, Margolese R. Body size and breast cancer prognosis: a statistical
explanation of the discrepancies. Cancer Res 49: 3113-6, 1989.
11. Pollak MN, Polychronakos C, Guyda H. Somatostatin analogue SMS 201-995 reduces serum IGF-1 levels
in patients with neoplasms potentially dependent on IGF-1. Anticancer Res 9: 889-91, 1989.
1990
12. Pollak M, Richard M. Suramin blockade of insulin-like growth factor I- stimulated proliferation of human
osteosarcoma cells. J Natl Cancer Inst 82: 1349-52, 1990.
13. Pollak MN, Polychronakos C, Richard M. Insulin-like growth factor 1: a potent mitogen for human
osteogenic sarcoma. J Natl Cancer Inst 82: 301-5, 1990.
14. Panasci L, Shenouda G, Begin L, Pollak M, Reinke A, Margolese R. Mitomycin C and mitoxantrone
chemotherapy for advanced breast cancer: efficacy with minimal gastrointestinal toxicity and alopecia.
Cancer Chemother Pharmacol 26: 457-60, 1990.
15. Pollak M, Costantino J, Polychronakos C, Blauer SA, Guyda H, Redmond C, Fisher B, Margolese R. Effect
of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J Natl Cancer
Inst 82: 1693-7, 1990. [see also favorable editorial comment: J Natl Cancer Inst 82: 1662-3, 1990].
1991
16. Dawson NA, Costanza ME, Korzun AH, Clamon GH, Pollak M, Vogelzang NJ, Carey RW, Norton L.
Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and
Leukemia Group B study. Med Pediatr Oncol 19: 283-8, 1991.
17. Pollak M, Boyarsky A, Gora P. A mathematical model describing consequences of abnormally high levels
of epidermal growth factor receptor on the proliferation of neoplastic cells. Cancer Invest 9: 513-20,
1991.
18. *Yao XJ, Wainberg MA, Richard M, Pollak M. The ability of suramin to block CD4-gp120 binding is
reversed in the presence of albumin. Antimicrob Agents Chemother 35: 2636-8, 1991.
19
19. *Yao XJ, Wainberg MA, Pollak M. The inhibitory effects of suramin on HIV-1 are attenuated in the
presence of albumin. AIDS 5: 1389-91, 1991.
1992
20. *Malaab SA, Pollak MN, Goodyer CG. Direct effects of tamoxifen on growth hormone secretion by
pituitary cells in vitro. Eur J Cancer 28A: 788-93, 1992.
21. Tannenbaum G, Gurd W, Lapointe M, Pollak M. Tamoxifen attenuates pulsatile growth hormone
secretion: mediation in part by somatostatin. Endocrinology 130: 3395-401, 1992.
22. Pollak M, Sem A, Richard M, Tetenes E, Bell R. Inhibition of metastatic behavior of murine osteosarcoma
by hypophysectomy. J Natl Cancer Inst 84: 966-71, 1992.
23. Pollak MN, Huynh HT, Lefebvre SP. Tamoxifen reduces serum-like growth factor I (IGF-I). Breast Cancer
Res Treat 22: 91-100, 1992.
24. Pollak M, Galant K, Poisson R, Harris A. Potential role for somatostatin analogues in breast cancer:
rationale and description of an ongoing trial. Metabolism 41: 9 Suppl 2, 119-20, 1992.
1993
25. *Friedl A, Jordan VC, Pollak M. Suppression of serum insulin-like growth factor-I levels in breast cancer
patients during adjuvant tamoxifen therapy. Eur J Cancer 29A: 1368-72, 1993.
26. *Huynh H, Tetenes E, Wallace L, Pollak M. In vivo inhibition of insulin-like growth factor 1 gene
expression by tamoxifen. Cancer Res 53: 1727-30, 1993.
27. Pollack R, Pollak M, Rochon L. Pregnancy complicated by medulloblastoma with metastases to the
placenta. Obstet Gynecol 81: 858-9, 1993.
28. *Pratt SE, Pollak MN. Estrogen and antiestrogen modulation of MCF7 human breast cancer cell
proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding
proteins in conditioned media. Cancer Res 53: 5193-8, 1993.
29. Tonin P, Ehrenborg E, Lenoir G, Feunteun J, Lynch H, Morgan K, Zazzi H, Vivier A, Pollak M, Huynh H, et
al. The human insulin-like growth factor- binding protein 4 gene maps to chromosome region 17q12q21.1 and is close to the gene for hereditary breast-ovarian cancer. Genomics 18: 414-7, 1993.
30. *Huynh H, Pollak M. Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen
and inhibited by the pure antiestrogen ICI 182780. Cancer Res 53: 5585-8, 1993.
1994
31. *Pratt SE, Pollak MN. Insulin-like growth factor binding protein 3 (IGF-BP3) inhibits estrogen-stimulated
breast cancer cell proliferation. Biochem Biophys Res Commun 198: 292-7, 1994.
20
32. *Sekyi-Otu A, Bell R, Andrulis I, Pollak M. Metastatic behavior of the RIF-1 murine fibrosarcoma:
inhibited by hypophysectomy and partially restored by growth hormone replacement. J Natl Cancer Inst
86: 628-32, 1994.
33. *Huynh H, Pollak M. Uterotrophic actions of estradiol and tamoxifen are associated with inhibition of
uterine insulin-like growth factor binding protein 3 gene expression. Cancer Res 54: 3115-9, 1994.
34. *Huynh H, Pollak M. Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene
expression and serum level by a somatostatin analogue. Biochem Biophys Res Commun 203: 253-9, 1994.
35. Weckbecker G, Tolcsvai L, Stolz B, Pollak M, Bruns C. Somatostatin analogue octreotide enhances the
antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz (alpha) anthracene-induced
rat mammary carcinomas. Cancer Res 54: 6334-7, 1994. [A footnote identifies Dr. Pollak and Dr. Bruns as
co-senior authors who contributed equally to this work.]
1995
36. *Huynh H, Pollak M. HH2A, an immortalized bovine breast epithelial cell line, expresses the gene
encoding mammary derived growth inhibitor. In Vitro Cell Dev Biol Anim 31: 25-9, 1995.
37. Rosenberg L, Barkun A, Denis MH, Pollak M. Low dose octreotide and tamoxifen in the treatment of
adenocarcinoma of the pancreas. Cancer 75: 23-8, 1995.
38. *Sekyi-Otu A, Bell RS, Ohashi C, Pollak M, Andrulis IL. Insulin-like growth factor I (IGF-I) receptors, IGF-I,
and IGF-2 are expressed in primary human sarcomas. Cancer Res 55: 129-34, 1995.
39. Bloom C, Lisbona A, Begin LR, Pollak M. Extraosseous Ewing's sarcoma. Can Assoc Radiol J 46: 131-3,
1995.
40. *Huynh HT, Larsson C, Narod S, Pollak M. Tumor suppressor activity of the gene encoding mammaryderived growth inhibitor. Cancer Res 55: 2225-31, 1995.
41. Montaner J, Harris A, Amar J, Fanning M, and multicenter study group (including Pollak M). Octreotide
therapy in AIDS-related refractory diarrhea: results of a multicenter Canadian-European study. AIDS 9:
209-10, 1995.
42. *Huynh H, Pollak M. Regulation of IGFBP-3 expression in breast cancer cells and uterus by estradiol and
antiestrogens: correlations with effects on proliferation: a review. Prog Growth Factor Res 6: 495-501,
1995.
1996
43. *Yang XF, Beamer WG, Huynh H, Pollak M. Reduced growth of human breast cancer xenografts in hosts
homozygous for the lit mutation. Cancer Res 56: 1509-11, 1996.
44. *Phelan C, Larsson C, Baird S, Futreal A, Ruttledge M, Morgan K, Tonin P, Huynh H, Korneluk R, Pollak M,
Narod S. The human mammary-derived growth inhibitor (MDGI) gene: genomic structure and mutation
analysis in human breast tumors. Genomics 34: 63-8, 1996. [Dr. Pollak and Dr. Narod are co-senior
authors who contributed equally to this work]
21
45. *Huynh H, Alpert L, Pollak M. Silencing of the mammary-derived growth inhibitor (MDGI) gene in breast
neoplasms is associated with epigenetic changes. Cancer Res 56: 4865-70, 1996.
46. *Huynh H, Yang X, Pollak M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth
factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 271: 1016-21, 1996.
47. Pollak M. Peptide growth factors and breast cancer treatment: recent translational research. Recent
Results Cancer Res 140: 43-9, 1996.
48. Pollak M. Enhancement of the anti-neoplastic effects of tamoxifen by somatostatin analogues. Digestion
57: 29-33, 1996.
49. *Huynh H, Alpert L, Pollak M. Pregnancy-dependent growth of mammary tumors is associated with
overexpression of insulin-like growth factor II. Cancer Res 56: 3651-4, 1996.
50. *Huynh H, Yang XF, Pollak M. A role for insulin-like growth factor binding protein 5 in the
antiproliferative action of the antiestrogen ICI 182780. Cell Growth Differ 7: 1501-6, 1996.
51. *Huynh H, Nickerson T, Pollak M, Yang X. Regulation of IGF-I receptor expression by the pure
antiestrogen ICI 182780. Clin Cancer Res 2: 2037-42, 1996.
1997
52. *Rozen F, Yang X, Huynh H, Pollak M. Antiproliferative action of vitamin D-related compounds and
insulin-like growth factor binding protein 5 accumulation. J Natl Cancer Inst 89: 652-6, 1997.
53. Karp SE, Tonin PN, Begin LR, Martinez JJ, Zhang JC, Pollak MN, Foulkes WD. Influence of BRCA1
mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish
women. Cancer 80: 435-41, 1997.
54. *Nickerson T, Huynh H, Pollak M. IGFBP-3 induces apoptosis in MCF7 breast cancer cells. Biochem
Biophys Res Commun 237: 690-3, 1997.
55. *Huynh H, Pollak M. Stabilization of mammary-derived growth inhibitor messenger RNA by
antiestrogens. Clin Cancer Res 3: 2151-6, 1997.
56. Foulkes WD, Wong N, Brunet JS, Begin LR, Zhang JC, Martinez JJ, Rozen F, Tonin PN, Narod SA, Karp SE,
Pollak MN. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with
breast cancer. Clin Cancer Res 3: 2465-9, 1997.
57. *Huynh H, Beamer W, Pollak M. Overexpression of IGFBP-4 by MCF-7 breast cancer cells is associated
with reduced responsiveness to IGFs in vitro and reduced tumor growth in vivo. Int J Oncol 11: 193-7,
1997.
58. Pollak M. The potential role of somatostatin analogues in breast cancer treatment. Yale J
Biol Med 70: 535-9, 1997.
1998
22
59. *Nickerson T, Pollak M, Huynh H. Castration-induced apoptosis in the rat ventral prostate is associated
with increased expression of genes encoding IGF binding proteins 2, 3, 4, and 5. Endocrinology 139: 80710, 1998.
60. Pollak MN, Schally AV. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc for Exp
Biol Med 217: 143-52, 1998.
61. *Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma
insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-6, 1998. [see
also favorable editorial comment – Science 279: 475, 1998]
62. Pollak MN. Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential
relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res. Treat 47: 209-17,
1998.
63. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M.
Circulating concentrations of insulin-like growth factor I and risk of breast cancer. Lancet 351: 1393-6,
1998. [see also favorable editorial comment: Lancet 351: 1373-4, 1998]
64. Pollak M. Effects of anti-estrogens on insulin-like growth factor-I physiology systemically and in the
uterus. Eur J Cancer 34: (Supp 4) S1-S8, 1998.
65. *Huynh H, Pollak M, Zhang JC. Regulation of IGF-II and IGF binding protein 3 autocrine loop in human PC3 prostate cancer cells by vitamin D metabolite 1,25(OH)2D3 and its analog EB1089. Int J Oncol 13: 13743, 1998.
66. *Rozen F, Zhang J, Pollak M. Antiproliferative action of tumor necrosis factor-alpha on MCF-7 breast
cancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation. Int J
Oncol 13: 865-9, 1998.
67. *Burrow S, Andrulis IL, Pollak M, Bell RS. Expression of insulin-like growth factor receptor, IGF-1, and IGF2 in primary and metastatic osteosarcoma. J Surg Oncol 69: 21-7, 1998.
1999
68. Ingle JN, Suman VJ, Kardinal CG, Krook JE, Mailliard JA, Veeder MH, Loprinzi CL, Dalton RJ, Hartmann LC,
Conover CA, Pollak MN. A randomized trial of tamoxifen alone or combined with octreotide in the
treatment of women with metastatic breast carcinoma. Cancer 85: 1284-92, 1999.
69. *Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ. Prospective study of
colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding
protein 3. J Natl Cancer Inst 91: 620-5, 1999. [see also favorable editorial comment- J Natl Cancer Inst 91:
579-81, 1999]
70. Pollak M, Beamer W, Zhang JC. Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev
17: 383-90, 1998-1999.
71. Pollak M. IGF-I physiology and breast cancer. Recent Results Cancer Res 152: 63-70, 1998.
23
72. Rosen C, Pollak M. Circulating IGF-I: New Perspective for a New Century. Trends Endocrinol Metab 10:
136-141, 1999.
73. *Nickerson T, Zhang J, Pollak M. Regression of DMBA-induced breast carcinoma following ovariectomy is
associated with increased expression of genes encoding insulin-like growth factor binding proteins. Int J
Oncol 14: 987-90, 1999.
74. *Nickerson T, Miyake H, Gleave M, Pollak M. Castration-induced apoptosis of androgen-dependent
shinogi carcinoma is associated with increased expression of genes encoding IGF-binding proteins.
Cancer Res 59: 3392-5, 1999.
75. *Rozen F, Pollak M. Inhibition of insulin-like growth factor 1 receptor signaling by the vitamin D analogue
EB1089 in MCF-7 breast cancer cells: A role for insulin-like growth factor binding proteins. Int J Oncol 15:
589-94, 1999.
76. Buhlmann C, Borchers T, Pollak M, Spener F. Fatty acid metabolism in human breast cancer cells (MCF7)
transfected with heart-type fatty acid binding protein. Mol Cell Biochem 199: 41-8, 1999.
77. *Nickerson T, Pollak M. Bicalutamide (Casodex)-induced prostate regression involves increased
expression of genes encoding insulin-like growth factor binding proteins. Urology 54: 1120-5, 1999.
78. Platz EA, Pollak MN, Rimm EB, Majeed N, Tao Y, Willett WC, Giovannucci E. Racial variation in insulin-like
growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol Biomarkers
Prev 8: 1107-10, 1999.
2000
79. Huynh H, Beamer W, Pollak M, Chan TW. Modulation of transforming growth factor beta1 gene
expression in the mammary gland by insulin-like growth factor I and octreotide. Int J Oncol 16: 277-81,
2000.
80. Miyake H, Pollak M, Gleave ME. Castration-induced up-regulation of IGFBP-5 potentiates IGF-I activity
and accelerates progression to androgen independence in prostate cancer models. Cancer Res 60: 305864, 2000.
81. Foulkes WD, Chappuis PO, Wong N, Brunet JS, Vesprini D, Rozen F, Yuan ZQ, Pollak MN, Kuperstein G,
Narod SA, Begin LR. Primary node negative breast cancer in BRCA1 mutation carriers has a poor
outcome. Ann Oncol 3: 307-13, 2000.
82. Giovannucci E, Pollak MN, Platz EA, Willett WC, Stampfer MJ, Majeed N, Colditz GA, Speizer FE,
Hankinson SE. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk
of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 9: 345-9, 2000.
83. Pollak M. Insulin-like growth factor physiology and cancer risk. Eur J Cancer 36: 1224-8, 2000.
84. Platz EA, Pollak MN, Willett WC, Giovannucci E. Vertex balding, plasma insulin-like growth factor 1, and
insulin-like growth factor binding protein 3. J Am Acad Dermatol 42: 1003-7, 2000.
85. Wilkin F, Paquette J, Ledru E, Mamelin C, Pollak M, Deal CL. H19 sense and antisense transgenes modify
insulin-like growth factor-II mRNA levels. Eur J Biochem 267: 4020-7, 2000.
24
86. Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE. Plasma insulin-like growth factor
(IGF) I, IGF-binding protein 3, and mammographic Density. Cancer Res 60: 3744-8, 2000.
87. * Zi X, Zhang J, Agarwal R, Pollak M. Silibinin up-regulates insulin-like growth factor-binding protein 3
expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res 60:
5617-20, 2000.
88. Pollak M. The question of a link between insulin-like growth factor physiology and neoplasia. Growth
Horm IGF Res 10 Suppl B: 21-4, 2000.
89. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M.
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal
women: results of a North American multicenter randomized trial. J Clin Oncol 18: 3758-67, 2000.
2001
90. Jernstrom H, Deal C, Wilkin F, Chu W, Tao Y, Majeed N, Hudson T, Narod SA, Pollak M. Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like
growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev
10: 377-84, 2001.
91. Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B, Hudson T, Stampfer M, Pollak M. Novel promoter
polymorphism in IGFBP3: correlation with serum levels and interaction with known regulators. J Clin
Endocrinol Metab 86: 1274-80, 2001.
92. Jernstrom H, Chu W, Vesprini D, Tao Y, Majeed N, Deal C, Pollak M, Narod SA. Genetic factors related to
racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast
cancer risk. Mol Genet Metab 72: 144-54, 2001.
93. Trojan DA, Collet J, Pollak MN, Shapiro S, Jubelt B, Miller RG, Agre JC, Munsat TL, Hollander D, Tandan R,
Robinson A, Finch L, Ducruet T, Cashman NR. Serum insulin-like growth factor-I (IGF-I) does not correlate
positively with isometric strength, fatigue, and quality of life in post-polio syndrome. J Neurol Sci 182:
107-15, 2001.
94. Pollak M. Insulin-like growth factors and prostate cancer. Epidemiol Rev 23: 59-66, 2001.
95. Chokkalingam AP, McGlynn KA, Gao YT, Pollak M, Deng J, Sesterhenn IA, Mostofi FK, Fraumeni JF Jr,
Hsing AW. Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk:
a population-based case-control study in China. Cancer Res 61: 4333-6, 2001.
96. Tolcher AW, Kennedy A, Padley RJ, Majeed N, Pollak M, Kantoff PW. Other novel agents: Rationale and
current status as chemopreventive agents. Urology 57: 86-9, 2001.
97. Pollak M, Blouin M-J, Zhang JC, Kopchick J.J. Reduced mammary gland carcinogenesis in transgenic mice
expressing a growth hormone antagonist. Br J Cancer 85: 428-30, 2001.
98. Chokkalingam AP, Pollak M, Fillmore C, Gao YT, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR,
Madigan MP, Ziegler RG, Fraumeni JF Jr, Hsing AW. Insulin-like growth factors and prostate cancer: a
population-based cased-control study in China. Cancer Epidemiol Biomarkers Prev 10: 421-7, 2001.
25
99. He B, Deckelbaum RA, Miao D, Lipman ML, Pollak M, Goltzman D, Karaplis AC. Tissue-specific targeting
of the pthrp gene: the generation of mice with floxed alleles. Endocrinology 142: 2070-7, 2001.
100. *Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M. In vivo of LAPC-9 and LNCaP
cancer models to androgen independence is associated with increased expression of IGF-I and IGF-IR.
Cancer Res 61: 6276-80, 2001.
101. Thorner M, and writing committee (including Pollak M). Critical evaluation of the safety of
recombinant human growth hormone administration: statement from the growth hormone research
society. J Clin Endocrin Metab 86: 1868-70, 2001.
102. Kucuk O, Sarkar FH, Sakr W, Djuric Z, Pollak MN, Khachik Y, Li YW, Banerjee M, Grignon D, Bertram JS,
Crissman JD, Pontes EJ, Wood DP Jr. Phase II randomized clinical trial of lycopene supplementation
before radical prostatectomy. Cancer Epidemiol Biomarkers Prev 10: 861-8, 2001.
103. Chan TW, Pollak M, Huynh H. Inhibition of insulin-like growth factor signaling pathways in mammary
gland by pure antiestrogen ICI 182,780. Clin Cancer Res 7: 2545-54, 2001.
104. Ma J, Giovannucci E, Pollak M, Chan JM, Gaziano JM, Willett W, Stampfer MJ. Milk intake, circulating
levels of insulin like growth factor-I and risk of colorectal cancer in men. J Natl Cancer Inst 93: 1330-6,
2001.
105. *Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and
resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93: 1852-7, 2001. [see also favorable editorial
comment- J Natl Cancer Inst 93: 1830-2, 2001].
2002
106. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E. Insulin-like growth factor-I
(IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94:
1099-106, 2002.
107. Giovannucci E, Pollak M. Risk of cancer after growth-hormone treatment. [editorial] Lancet 360: 2689, 2002.
108. Toppmeyer D, Seidman AD, Pollak M, Russell C, Tkaczuk K, Verma S, Overmoyer B, Garg V, Ette E,
Harding MW, Demetri GD. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin Cancer Res 8:
670-8, 2002.
109. Missmer SA, Haiman CA, Hunter DJ, Willett WC, Colditz GA, Speizer FE, Pollak MN, Hankinson SE. A
sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer. Int J Cancer 100: 3326, 2002.
110. Kucuk O, Sarkar FH, Sakr W, Khachik F, Djuric Z, Banerjee M, Pollak MN, Bertram JS, Wood DP.
Lycopene in the treatment of prostate cancer. Pure and Applied Chemistry 74: 1443-50, 2002.
26
111. Holmes MD, Pollak MN, Willett WC, Hankinson SE. Dietary correlates of plasma insulin-like growth
factor I and insulin-like growth factor binding protein-3 concentrations. Cancer Epidemiol Biomarkers
Prev 11: 852-61, 2002.
112. Holmes MD, Pollak MN, Hankinson SE. Lifestyle correlates of plasma insulin-like growth factor I and
insulin-like growth factor binding protein-3 concentrations. Cancer Epidemiol Biomarkers Prev 11: 862-7,
2002.
113. Deitel K, Dantzer D, Ferguson P, Pollak M, Beamer W, Andrulis I, Bell R. Reduced growth of human
sarcoma xenografts in hosts homozygous for the lit mutation. J Surg Oncol 81: 75-9, 2002.
114. Giovannucci E, Haiman CA, Platz EA, Hankinson SE, Pollak MN. Dinucleotide repeat in the insulin-like
growth factor-I gene is not related to risk of colorectal adenoma. Cancer Epidemiol Biomarkers Prev 11:
1509-10, 2002.
115. Spitz MR, Barnett MJ, Goodman GE, Thornquist MD, Wu X, Pollak M. Serum insulin-like growth factor
(IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the betaCarotene and Retinol Efficacy Trial Cohort. Cancer Epidemiol Biomarkers Prev 11: 1413-8, 2002.
116. Kucuk O, Sarkar FH, Djuric Z, Sakr W, Pollak MN, Khachik F, Banerjee M, Bertram JS, Wood DP Jr.
Effects of lycopene supplementation in patients with localized prostate cancer. Exp Biol Med 227: 881-5,
2002.
117. *Levitt RJ, Pollak M. Insulin-like growth factor-I antagonizes the antiproliferative effects of
cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells. Cancer Res 62: 7372-6, 2002.
118.
*Camirand A, Lu Y, Pollak M. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors
causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit 8:
BR521-6, 2002.
119. Ismail AH, Pollak M, Behlouli H, Tanguay S, Begin LR, Aprikian AG. Insulin-like growth factor-1 and
insulin-like growth factor binding protein-3 for prostate cancer detection in patients undergoing prostate
biopsy. J Urol 168: 2426-30, 2002.
2003
120. Giovannucci E, Pollak M, Liu Y, Platz EA, Majeed N, Rimm EB, Willet WC. Nutritional predictors of
insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev
12: 84-9, 2003.
121. Pollak MN, Foulkes W. Challenges to cancer control by screening. Nat Rev Cancer 3: 297-303, 2003.
122. Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ. Association of markers of insulin
and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 12: 412-8,
2003.
123. Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, Albanes D. Serum insulin-like
growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish
men. Cancer Res 63: 3991-4, 2003.
27
124. Nomura AM, Stemmermann GN, Lee J, Pollak MN. Serum insulin-like growth factor I and subsequent
risk of colorectal cancer among Japanese-American men. Am J Epidemiol 158: 424-31, 2003.
125. Schernhammer ES, Hankinson SE, Hunter DJ, Blouin MJ, Pollak MN. Polymorphic variation at the -202
locus in IGFBP3: Influence on serum levels of insulin-like growth factors, interaction with plasma retinol
and vitamin D and breast cancer risk. Int J Cancer 107: 60-4, 2003.
126. Ismail HA, Pollak M, Behlouli H, Tanguay S, Begin LR, Aprikian AG. Serum insulin-like growth factor
(IGF) – 1 and IGF-binding protein-3 do not correlate with Gleason score or quantity of prostate cancer in
biopsy samples. BJU Int 92: 699-702, 2003.
127. VanHouten JN, Dann P, Stewart AF, Watson CJ, Pollak M, Karaplis AC, Wysolmerski JJ. Mammaryspecific deletion of parathyroid hormone-related protein preserves bone mass during lactation. J Clin
Invest 112: 1429-36, 2003.
128. Nam RK, Zhang WW, Trachtenberg J, Jewett MA, Emami M, Vesprinin D, Chu W, Ho M, Sweet J, Evans
A, Toi A, Pollak M, Narod SA. Comprehensive assessment of candidate genes and serological markers for
the detection of prostate cancer. Cancer Epidemiol Biomarkers Prev 12: 1429-37, 2003.
129. Hussain M, Banerjee M, Sarkar FH, Djuric Z, Pollak MN, Doerge D, Fontana J, Chinni S, Davis J, Forman
J, Wood DP, Kucuk O. Soy isoflavones in the treatment of prostate cancer. Nutr Cancer 47: 111-7, 2003.
2004
130. *Lu Y, Zi X, Pollak M. Molecular mechanisms underlying IGF-I-induced attenuation of the growthinhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 108: 334-41,
2004.
131. *Lu Y, Zi X, Zhao Y, Pollak M. Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK
signaling pathway in breast cancer cells. Biochem Biophys Res Commun 313: 709-15, 2004.
132. Schairer C, Hill D, Fears T, Ziegler R, Hoover R, Pollak M. Serum concentrations of IGF-I, IGFBP-3, and cpeptide and risk of hyperplasia and cancer of the breast in postmenopausal women. Int J Cancer 108:
773-9, 2004.
133. *Levitt RJ, Buckley J, Blouin MJ, Schaub B, Triche TJ, Pollak M. Growth inhibiton of breast epithelial
cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3
expression. Biochem Biophys Res Commun 316: 421-8, 2004.
134. Labrie F, Champagne P, Labrie C, Roy J, Laverdiere J, Provencher L, Potvin M, Drolet Y, Pollak M,
Panasci L, L'Esperance B, Dufresne J, Latreille J, Robert J, Samson B, Jolivet J, Yelle L, Cusan L, Diamond P,
Candas B. Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in
tamoxifen-resistant breast cancer. J Clin Oncol 22: 864-71, 2004.
135. Ma J, Giovannucci EL, Pollak MN, Leavitt A, Tao Y, Gaziano JM, Stampfer MJ. A prospective study of
plasma c-peptide and colorectal cancer risk in men. J Natl Cancer Inst 96: 546-53, 2004.
136. Lai JH, Vesprini D, Zhang W, Yaffe MJ, Pollak M, Narod SA. A polymorphic locus in the promoter region
of the IGFBP3 gene is related to mammographic breast density. Cancer Epidemiol Biomarkers Prev 13:
573-82, 2004.
28
137. Stolzenberg-Solomon RZ, Limburg P, Pollak M, Taylor PR, Virtamo J, Albanes D. Insulin-like growth
factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers. Cancer Epidemiol
Biomarkers Prev 13: 438-44, 2004.
138. *Camirand A, Pollak M. Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and
induction of apoptosis in H 209 small cell lung cancer cells. Br J Cancer 90: 1825-9, 2004.
139. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Solicited
Review. Nature Rev Cancer 4: 505-18, 2004.
2005
140. Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M,
Fisher B, McKenna A, Seymour L. Randomized phase II study of two dose of gefitinib in hormonerefractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trial Group. J Clin
Oncol 23: 455-60, 2005.
141. Schernhammer ES, Holly JM, Pollak MN, Hankinson SE. Circulating levels of insulin-like growth factors,
their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 3: 699-704, 2005.
142. Kristal AR, King IB, Albanes D, Pollak MN, Stanzyk FZ, Santella RM, Hoque A. Centralized blood
precessing for the selenium and vitamin E cancer prevention trial: effects of delayed processing on
caroteniods, tocopherols, insulin-like growth factor-I, insulin-like growth factor binding protein 3, steroid
hormones, and lymphocyte viability. Cancer Epidemiol Biomarkers Prev 14: 727-30, 2005.
143. Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE, Giovannucci E. A prospective study of Cpeptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of
colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 14: 850-5, 2005.
144. Nam RK, Trachtenberg J, Jewitt MA, Toi A, Evans A, Narod SA, Pollak M. Serum insulin-like growth
factor-1 (IGF-1) levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-1
physiology and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 14: 1270-3, 2005.
145. Diorio C, Pollak M, Byrne C, Masse B, Hebert-Croteau N, Yaffe M, Cote G, Berube S, Morin C, Brisson J.
Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol
Biomarkers Prev 14: 1065-73, 2005.
146. Meyerhardt JA, Sloan JA, Sargent DJ, Goldberg RM, Pollak M, Morton RF, Ramanathan RK, Williamson
SK, Findlay BP, Fuchs CS. Associations between plasma insulin-like gowth factor proteins and c-peptide
and quality of life in patients with metastatic colorectal cancer. Cancer Epidemiol Biomarkers Prev 14:
1402-10, 2005.
147. Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E. Plasma insulin-like
growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer
Causes and Control 16: 255-62, 2005.
148. Sutherland BW, Kucab J, Wu J, Lee C, Cheang MC, Yorida E, Turbin D, Dedhar S, Nelson C, Pollak M,
Leighton Grimes H, Miller K, Badve S, Huntsman D, Blake-Gilks C, Chen M, Pallen CJ, Dunn SE. Akt
29
phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the
anchorage-independent growth of breast cancer cells. Oncogene 24: 4281-92, 2005.
149. *Camirand A, Zakikhani M, Young F, Pollak M. Inhibition of insulin-like growth factor-1 receptor
signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast
cancer cells. Breast Cancer Res 7: R570-9, 2005.
150. *Majeed N, Blouin MJ, Kaplan-Lefko PJ, Barry-Shaw J, Greenberg NM, Gaudreau P, Bismar TA, Pollak
M. A germ line mutation that delays prostate cancer progression and prolongs survival in a murine
prostate cancer model. Oncogene 24: 4736-40, 2005.
151. Berube S, Diorio C, Masse B, Herbert-Croteau N, Byrne C, Cote G, Pollak M, Yaffe M, Brisson J. Vitamin
D and calcium intakes from food or supplements and mammographic breast density. Cancer Epidemiol
Biomarkers Prev 14: 1553-9, 2005.
152. Pinheiro SP, Holmes MD, Pollak MN, Barieri RL, Hankinson SE. Racial differences in premenopausal
endogenous hormones. Cancer Epidemiol Biomarkers Prev 14: 2147-53, 2005.
153. Kucab JE, Lee C, Chen CS, Zhu J, Gilks CB, Cheang M, Huntsman D, Yorida E, Emerman J, Pollak M, Dunn
SE. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours.
Breast Cancer Res 7: R796-807, 2005.
154. *Levitt RJ, Georgescu MM, Pollak M. PTEN-induction in U251 glioma cells decreases the expression of
insulin-like growth factor binding protein-2. Biochem Biophys Res Commun 336: 1056-61, 2005.
155. Diorio C, Pollak M, Byrne C, Masse B, Hebert-Croteau N, Yaffe M, Cote G, Berube S, Brisson J. Levels of
C-peptide and mammographic breast density. Cancer Epidemiol Biomarkers Prev 14: 2661-4. 2005.
2006
156. Diorio C, Berube S, Byrne C, Masse B, Hebert-Croteau N, Yaffe M, Cote G, Pollak M, Brisson J. Influence
of insulin-like growth factors on the strength of the relation of vitamin D and calcium intakes to
mammographic breast density. Cancer Res 66: 588-97, 2006.
157. Rollison DE, Newschaffer CJ, Tao Y, Pollak M, Helzlsouer KJ. Premenopausal levels of circulating insulinlike growth factor I and the risk of postmenopausal breast cancer. Int J Cancer 118: 1279-84, 2006.
158. Rousseau MC, Parent ME, Pollak MN, Siemiatycki J. Diabetes mellitus and cancer risk in a populationbased case-control study among men from Montreal, Canada. Int J Cancer 118: 2105-9, 2006.
159. Gotlieb WH, Bruchim I, Gu J, Shi Y, Camirand A, Blouin MJ, Zhao Y, Pollak MN. Insulin-like growth
factor receptor I targeting in epithelial ovarian cancer. Gynecol Oncol 100: 389-96, 2006.
160. Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE, Giovannucci E. C-peptide, insulin-like growth
factor binding protein-1, glycosylated hemoglobin, and the risk of distal colorectal adenoma in women.
Cancer Epidemiol Biomarkers Prev 15: 750-5, 2006.
161. Harris TG, Strickler HD, Yu H, Pollak MN, Monrad ES, Travin MI, Xue X, Rohan TE, Kaplan RC. Specimen
processing time and measurement of total insulin-like growth factor-I (IGF-I), free IGF-I, and IGF binding
protein-3. Growth Horm IGF Res 16: 86-92, 2006.
30
162. Missmer SA, Spiegelman D, Bertone-Johnson ER, Barbieri RL, Pollak MN, Hankinson SE. Reproducibility
of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal
women over a 2- to 3-year period. Cancer Epidemiol Biomarkers Prev 15: 972-8, 2006.
163. Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE. Insulin-like growth factor-I, its
binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses
Health Study II. Endocr Relat Cancer 13: 583-92, 2006.
164. Tseng PH, Weng SC, Wang YC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE,
Pollak M, Chen CS. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by
using a novel celecoxib-derived PDK-1 inhibitor. Mol Pharmacol 70: 1534-41, 2006.
165. *Zakikhani M, Dowling R, Fantus GI, Sonenberg N, Pollak M. Metformin is an AMP-kinase dependent
growth inhibitor for breast cancer cells. Cancer Res 66: 10269-73, 2006.
166. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, Lippman SM, Platz EA, Pollak MN,
Thompson IM, Kristal AR. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer
prevention trial. Epidemiol Biomarkers Prev 15: 1977-83, 2006.
167. Ahn J, Weinstein SJ, Snyder K, Pollak MN, Virtamo J, Albanes D. No association between serum insulinlike growth factor (IGF)-I, IGF-binding protein-3, and lung cancer risk. Cancer Epidemiol Biomarkers Prev
15: 2010-2, 2006.
168. Tran CD, Diorio C, Berube S, Pollak M, Brisson J. Relation of insulin-like growth factor (IGF) I and IGFbinding protein 3 concentrations with intakes of fruit, vegetables, and antioxidants. Am J Clin Nutr 84:
1518-26, 2006.
2007
169. Liu B, Lee KW, Anzo M, Zhang B, Zi X, Tao Y, Shiry L, Pollak M, Lin S, Cohen P. Insulin-like growth
factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis.
Oncogene 26: 1811-9, 2007.
170. Okereke O, Kang JH, Ma J, Hankinson SE, Pollak MN, Grodstein F. Plasma IGF-I levels and cognitive
performance in older women. Neurobiol Aging 28: 135-42, 2007.
171. Eliassen AH, Tworoger SS, Mantzoros CS, Pollak MN, Hankinson SE. Circulating insulin and c-peptide
levels and risk of breast cancer among predominately premenopausal women. Cancer Epidemiol
Biomarkers Prev 16: 161-4, 2007.
172. Pollak M. Insulin-like growth factor-related signaling and cancer development. Recent Results Cancer
Res 174: 49-53, 2007.
173. Tamimi RM, Cox DG, Kraft P, Pollak MN, Haiman CA, Cheng I, Freedman ML, Hankinson SE, Hunter DJ,
Colditz GA. Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic
density: a cross-sectional study. Br Cancer Res 9: R18, 2007.
31
174. Kaplan RC, McGinn AP, Pollak MN, Kuller LH, Strickler HD, Rohan TE, Cappola AR, Xue X, Psaty BM.
Association of total IGF-I, IGFBP-1 and IGFBP-3 levels with incident coronary events and ischemic stroke.
J Clin Endocrinol Metab 92: 1319-25, 2007.
175. Schaffer A, Koushik A, Trottier H, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L,
Gotlieb W, Ferenczy A, Coutlee F, Pollak MN, Franco EL; Biomarkers of Cervical Cancer Risk Study Team.
Insulin-like growth factor-I and risk of high-grade cervical intraepithelial neoplasia. Cancer Epidemiol
Biomarkers Prev 16: 716-22, 2007.
176. Lonn S, Inskip PD, Pollak MN, Weinstein SJ, Virtamo J, Albanes D. Glioma risk in relation to serum
levels of insulin-like growth factors. Cancer Epidemiol Biomarkers Prev 16: 844-6, 2007.
177. McSorley MA, Alberg AJ, Allen DS, Allen NE, Brinton LA, Dorgan JF, Pollak M, Tao Y, Helzlsouer KJ. Creactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol 109: 933-41, 2007.
178. Brisson J, Berube S, Diorio C, Sinotte M, Pollak M, Masse B. Synchronized seasonal variations of
mammographic breast density and plasma 25-hydroxyvitamin d. Cancer Epidemiol Biomarkers Prev 16:
929-33, 2007.
179. *Levitt RJ, Zhao Y, Blouin MJ, Pollak M. The hedgehog pathway inhibitor cyclopamine increase levels of
p27, and decreases both expression of IGF-II and activation of Akt in PC-3 prostate cancer cells. Cancer
Lett 255: 300-6, 2007.
180. de Bono JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P, Roberts L, Melvin C, Repollet M,
Chianese D, Connely M, Terstappen LW, Gualberto A. Potential applications for circulating tumor cells
expressing the insulin-like growth factor-I receptor. Clin Cancer Res 13: 3611-6, 2007.
181. Pollak MN. Insulin, insulin-like growth factors, insulin resistance, and neoplasia. Am J Clin Nutr 86:
S820-1, 2007.
182. Tworoger SS, Lee IM, Buring JE, Pollak MN, Hankinson SE. Insulin-like growth factors and ovarian risk: a
nested case-control study in three cohorts. Cancer Epidemiol Biomarkers Prev 16: 1691-5, 2007.
183. Li H, Bubley GJ, Balk SP, Gaziano JM, Pollak M, Stampfer MJ, Ma J. Hypoxia-inducible factor-1 alpha
gene polymorphisms, circulating insulin-like growth factor binding protein-3 levels and prostate cancer.
Prostate 67: 1354-61, 2007.
184. Wolpin BM, Michaud DS, Giovannucci EL, Schernhammer ES, Stampfer MJ, Manson JE, Cochrane BB,
Rohan TE, Ma J, Pollak MN, Fuchs CS. Circulating insulin-like growth factor binding protein-1 and the risk
of pancreatic cancer. Cancer Res 67: 7923-8, 2007.
185. Michaud DS, Wolpin B, Giovannucci E, Liu S, Cochrane B, Manson JE, Pollak MN, Ma J, Fuchs CS.
Prediagnostic plasma C-Peptide and pancreatic cancer risk in men and women. Cancer Epidemiol
Biomarkers Prev 16: 2101-9, 2007.
186. Wolpin BM, Michaud DS, Giovannucci EL, Schernhammer ES, Stampfer MJ, Manson JE, Cochrane BB,
Rohan TE, Ma J, Pollak MN, Fuchs CS. Circulating insulin-like growth factor axis and the risk of pancreatic
cancer in four prospective cohorts. Br J Cancer 97: 98-104, 2007.
32
187. Schernhammer ES, Tworoger SS, Eliassen AH, Missmer SA, Holly JM, Pollak MN, Hankinson SE. Body
shape throughout life and correlations with IGFs and GH. Endocr Relat Cancer 14: 721-32, 2007.
188. Rich-Edwars JW, Ganmaa D, Pollak MN, Nakamoto EK, Kleinman K, Tserendolgor U, Willett WC, Frazier
AL. Milk consumption and the prepubertal somatotropic axis. Nutr J 6: 28, 2007.
189. Borugian MJ, Spinelli JJ, Sun Z, Kolonel LN, Oakley-Girvan I, Pollak M, Whittemore AS, Wu AH,
Gallagher RP. Prediagnostic C-peptide and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 16:
2164-5, 2007.
190. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of
rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67: 10804-12, 2007.
191. Raina K, Blouin MJ, Singh RP, Majeed N, Deep G, Varghese L, Glode LM, Greenberg NM, Hwang D,
Cohen P, Pollak MN, Agarwal R. Dietary feeding of silibinin inhibits prostate tumor growth and
progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 67: 11083-91, 2007.
192. Singh RP, Deep G, Blouin MJ, Pollak MN, Agarwal R. Silibinin suppresses in vivo growth of human
prostate carcinoma PC-3 tumor xenograft. Carcinogenesis 28: 2567-74, 2007.
193. Venkateswaran V, Haddad AQ, Fleshner NE, Fan R, Sugar LM, Nam R, Klotz LH, Pollak M. Association of
diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl
Cancer Inst 99: 1793-800, 2007.
2008
194. Rajpathak SN, McGinn AP, Strickler HD, Rohan TE, Pollak M, Cappola AR, Kuller L, Xue X, Newman AB,
Strotmeyer ES, Psaty BM, Kaplan RC. Insulin-like growth factor-axis, inflammation, and glucose
intolerance among older adults. Growth Horm IGF Res 18: 166-73, 2008.
195. Borugian MJ, Spinelli JJ, Sun Z, Kolonel LN, Oakley-Girvan I, Pollak M, Whittemore AS, Wu AH,
Gallagher RP. Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein3: a prospective multiethnic study. Cancer Epidemiol Biomarkers Prev 17: 252-4, 2008.
196. Okereke OI, Pollak MN, Hu FB, Hankinson SE, Selkoe DJ, Grodstein F. Plasma C-peptide levels and rates
of cognitive decline in older, community-dwelling women without diabetes. Psychoneuroendocrinology
33: 455-61, 2008.
197. Kaplan RC, McGinn AP, Pollak MN, Kuller L, Strickler HD, Rohan TE, Xue X, Kritchevsky SB, Newman AB,
Psaty BM. Total insulin like growth factor 1 and insulin like growth factor binding protein levels,
functional status, and mortality in older adults. J Am Geriatr Soc 56: 652-60, 2008.
198. Kasper JS, Liu Y, Pollak MN, Rifai N, Giovannucci E. Hormonal profile of diabetic men and the potential
link to prostate cancer. Cancer Causes Control 19: 703-10, 2008.
199. Ades S, Koushik A, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W,
Ferenczy A, Coutlée F, Roger M, Franco EL; Biomarkers of Cervical Cancer Risk (BCCR) Study Team
(Michael Pollak is member). Selected class I and class II HLA alleles and haplotypes and risk of high-grade
cervical intraepithelial neoplasia. Int J Cancer 122: 2820-6, 2008.
33
200. Diorio C, Brisson J, Berube S, Pollak M. Genetic polymorphisms involved in insulin-like growth factor
(IGF-I) pathway in relation to mammographic breast density and IGF levels. Cancer Epidemiol Biomarkers
Prev 17: 880-8, 2008.
201. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, Harris TG, Rohan TE, Xue X, Ho GY,
Einstein MH, Kaplan RC, Burk RD, Wylie-Rosett J, Pollak MN, Anderson G, Howard BV, Strickler HD. A
prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer.
Cancer Epidemiol Biomarker Prev 17: 921-9, 2008.
202. van Oijen M, Okereke OI, Kang JH, Pollak MN, Hu FB, Hankinson SE, Grodstein F. Fasting insulin levels
and cognitive decline in older women without diabetes. Neuroepidemiology 30: 174-9, 2008.
203. *Algire C, Zakikhani M, Blouin MJ, Shuai JH, Pollak M. Metformin attenuates the stimulatory effect of a
high energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer 15: 833-9, 2008.
204. Diorio C, Brisson J, Berube S, Pollak M. Intact and total insulin-like growth factor-binding protein-3
levels in relation to breast cancer risk factors: a cross-sectional study. Br Cancer Res 10: R42, 2008.
205. Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D, Sharma A, Enriquez Sarano M, Pollak
M, Jagannath S, Richardson P, Gualberto A. Phase I, pharmacokinetic and pharmacodynamic study of the
anti-insulin like growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple
myeloma. J Clin Oncol 26: 3196-203, 2008.
206. Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN, Bruchim I. In vitro metformin antineoplastic activity in epithelial ovarian cancer. Gynecol Oncol. 110: 246-50, 2008.
207. Kaplan RC, McGinn AP, Pollak MN, Kuller L, Strickler HD, Rohan TE, Cappola AR, Xue X, Psaty BM. High
insulin like growth factor binding protein 1 level predicts incident congestive heart failure in the elderly.
Am Heart J 155: 1006-12, 2008.
208. Max JB, Limburg PJ, Ogunseitan A, Stolzenberg-Solomon RZ, Vierkant RA, Pollak M, Sellers TA, Virtamo
J, Cerhan JR, Albanes D. IGF-I, IGFBP-3, and IGF-I/IGFBP-3 Ratio: No Association with Incident Colorectal
Cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Cancer Epidemiol Biomarkers
Prev 17: 1832-4, 2008.
209. Neuhouser ML, Schenk J, Song YJ, Tangen CM, Goodman PJ, Pollak M, Penson DF, Thompson IM,
Kristal AR. Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign
prostate hyperplasia in the prostate cancer prevention trial. Prostate 68: 1477-86, 2008.
210. Patel AV, Cheng I, Canzian F, Le Marchand L, Thun MJ, Berg CD, Buring J, Calle EE, Chanock S, ClavelChapelon F, Cox DG, Dorronsoro M, Dossu L, Haiman CA, Hankinson SE, Henderson BE, Hoover R, Hunter
DJ, Kaaks R, Kolonel LN, Kraft P, Linseisen J, Lund E, Manjer J, McCarty C, Peeters PH, Pike MC, Pollak M,
Riboli E, Stram DO, Tjonneland A, Travis RC, Trichopoulos D, Tumino R, Yeager M, Ziegler RG, Feigelson
HS; Breast and Prostate Cancer Cohort Consortium. IGF-1, IGFBP-1, IGFBP-3 polymorphisms predict
circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort
Consortium (BPC3). PLoS ONE 3: e2578, 2008.
211. Page JH, Ma J, Pollak M, Manson JE, Hankinson SE. Plasma insulin-like growth factor 1 and bindingprotein 3 and risk of myocardial infarction in women: a prospective study. Clin Chem 54: 1682-8, 2008.
34
212. Pollak M. Targeting insulin and insulin-like growth factor signalling in oncology. Curr Opin Pharmacol 8:
384-92, 2008.
213. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen P, Gaziano JM, Pollak M, Stampfer M. Prediagnostic
body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with
prostate cancer: a long-term survival analysis. Lancet Oncol 9: 1039-47, 2008.
214. *Zakikhani M, Dowling RJO, Sonenberg N, Pollak MN. Effects of adiponectin and metformin on
prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res 1: 36975, 2008.
215. Diorio C, Sinotte M, Brisson J, Berube S, Pollak M. Vitamin d pathway polymorphisms in relation to
mammographic breast density. Cancer epidemiol Biomarkers Prev 17: 2505-8, 2008.
216. Fuchs CS, Goldberg RM, Sargen DJ, Meyerhardt JA, Wolpin BM, Green EM, Pitot HC, Pollak M. Plasma
insulin-like growth factors, insulin-like binding protein-3 and outcome in metastatic colorectal cancer:
results from intergroup trial N9741. Clin Cancer Res 14: 8263-9, 2008.
217. Stolzenberg-Solomon RZ, Weinstein S, Pollak M, Tao Y, Taylor PR, Virtamo J, Albanes D. Prediagnostic
adiponectin concentrations and pancreatic cancer risk in male smokers. Am J Epidemiol 168: 1047-55,
2008.
218. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS,
Fitzpatrick A, Hsing AW, Lacey JV Jr, Helzlsouer K, Rinaldi S, Riboli E, Kaaks R, Janssen JA, Wildhagen MF,
Schröder FH, Platz EA, Pollak M, Giovannucci E, Schaefer C, Quesenberry CP Jr, Vogelman JH, Severi G,
English DR, Giles GG, Stattin P, Hallmans G, Johansson M, Chan JM, Gann P, Oliver SE, Holly JM, Donovan
J, Meyer F, Bairati I, Galan P. Insulin-like growth factors, their binding proteins, and prostate cancer risk:
analysis of individual patient data from 12 prospective studies. Ann Intern Med 149: 461-71,W83-8,
2008.
219. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like growth factor
receptor pathway. Clin Cancer Res 14: 6364-70, 2008.
220. Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn
SE. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease
specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res 10: R86,
2008.
221. Pollak M. Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer 8: 915-28, 2008.
222. So AI, Levitt RJ, Eigl B, Fazli L, Muramaki M, Leung S, Cheang MCU, Nielsen TO, Gleave M, Pollak M.
Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer.
Clin Cancer Res 14: 6944-54, 2008.
223. Pollak M. Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab 22:
625-38, 2008.
224. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE,
Nicholson RI, Carboni J, Gottardis M, Pollak M, Dunn SE. Phosphorylated insulin-like growth factor35
i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68:
10238-46, 2008.
2009
225. Okereke OI, Selkoe DJ, Pollak MN, Stampfer MJ, Hu FB, Hankinson SE, Grodstein F. A profile of
impaired insulin degradation in relation to late-life cognitive decline: A preliminary investigation. Int J
Geriatr Psychiatry 24: 177-82, 2009.
226. Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, Pollak MN, Giovannucci EL, Fuchs CS.
Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer.
J Clin Oncol 27: 176-85, 2009.
227. Sinotte M, Diorio C, Berube S, Pollak M, Brisson J. Genetic polymorphisms of the vitamin D binding
protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. Am J Clin Nutr 89:
634-40, 2009.
228. Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E, Cunningham M, Larsson O, Fazli L, Pollak
M. Insulin receptor expression by human prostate cancers. The Prostate 69: 33-40, 2009.
229. Pollak M. Energy metabolism, cancer risk, and cancer prevention. Recent Results Cancer Res 181: 51-4,
2009.
230. Avnet S, Sciacca L, Salerno M, Gancitano G, Cassarino MF, Longhi A, Zakikhani M, Carboni JM, Gottardis
M, Giunti A, Pollak M, Vigneri R, Baldini N. Insulin receptor isoform A and insulin-like growth factor II as
additional treatment targets in human osteosarcoma. Cancer Res 69: 2443-52, 2009.
231. Pollak M. Aging, IGF-1, and diet. Aging Cell 8: 214, 2009.
232. Kaplan RC, Fitzpatrick AL, Pollak MN, Gardner JP, Jenny NS, McGinn AP, Kuller LH, Strickler HD, Kimura
M, Psaty BM, Aviv A. Insulin-like growth factors and leukocyte telomere length: the cardiovascular health
study. J Gerontol A Biol Sci Med Sci 64: 1103-6, 2009.
233. Pollak M. Do cancer cells care if their host is hungry? Cell Metab 9: 401-3, 2009.
234. Rohrmann S, Sutcliffe CG, Bienstock JL, Monsegue D, Akereyeni F, Bradwin G, Rifai N, Pollak MN,
Agurs-Collins T, Platz EA. Racial variation in sex steroid hormones and the insulin-like growth factor axis
in umbilical cord blood male neonates. Cancer Epidemiol Biomarkers Prev 18: 1484-91, 2009.
235. Mavropoulos JC, Buschemeyer WC 3rd, Tewari AK, Fokhfeld D, Pollak M, Zhao Y, Febbo PG, Cohen P,
Hwang D, Devi G, Demark-Wahnefried W, Westman EC, Peterson BL, PIzzo SV, Freedland SJ. The effects
of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft
model. Cancer Prev Res (Phila Pa) 2: 557-65, 2009.
236. Dowling RJ, Pollak M, Sonenberg N. Current status and challenges associated with targeting mTOR for
cancer therapy. BioDrugs 23: 77-91, 2009.
237. Su X, Colditz GA, Willett WC, Collins LC, Schnitt SJ, Connolly JL, Pollak MN, Rosner B, Tamimi RM.
Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign
breast disease. Int J Cancer 126: 180-90, 2009.
36
238. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early
clinical trial results and future directions. Oncogene 28: 3009-21, 2009.
239. Pollak M. Macronutrient intake and cancer: how does dietary restriction influence tumor growth and
why should we care? Cancer Prev Res (Phila Pa) 2: 698-701, 2009.
240. Beauchamp MC, Knafo A, Yasmeen A, Carboni JM, Gottardis MM, Pollak MN, Gotlieb WH. BMS536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide.
Gynecol Oncol 115: 193-8, 2009.
241. Gualberto A, Pollak M. Clinical development of inhibitors of the insulin-like growth factor receptor in
oncology. Curr Drug Targets 10: 923-36, 2009.
242. Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, Yin D, Lipton A, Demers L, Leitzel K, Hixon ML,
Terstappen LW, Garland L, Paz-Ares LG, Cardenal F, Langer CJ, Gualberto A. Safety, pharmacokinetics,
and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor Figitumumab (CP751,871) in combination with Paclitaxel and Carboplatin. J Thorac Oncol 4: 1397-403, 2009.
243. Barbieri M, Paolisso G, Kimura M, Gardner JP, Boccardi V, Papa M, Hjelmborg JV, Christensen K,
Brimacombe M, Nawrot TS, Staessen JA, Pollak MN, Aviv A. Higher circulating levels of igf-1 are
associated with longer leukocyte telomere length in healthy subjects. Mech Ageing Dev 130: 771-6,
2009.
2010
244. Khalid S, Hwang D, Babichev Y, Kolli R, Altamentova S, Koren S, Goodwin PJ, Ennis M, Pollak M,
Sonenberg N, Fantus IG. Evidence for a tumor promoting effect of high-fat diet independent of insulin
resistance in HER2/Neu mammary carcinogenesis. Breast Cancer Res Treat 122: 647-59, 2010.
245. Tsilidis KK, Brancati FL, Pollak MN, Rifai N, Clipp SL, Hoffman-Bolton J, Helzlsouer KJ, Platz EA.
Metabolic syndrome components and colorectal adenoma in the CLUE II cohort. Cancer Causes Control
21: 1-10, 2010.
246. Mucci LA, Stark JR, Pollak MN, Li H, Kurth T, Stampfer MJ, Ma J. Plasma levels of acid-labile subunit,
free insulin-like growth factor-I, and prostate cancer risk: a prospective study. Cancer Epidemiol
Biomarkers Prev 19: 484-91, 2010.
247. *Zakikhani M, Blouin MJ, Piura E, Pollak MN. Metformin and rapamycin have distinct effects on the
AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 123: 271-9, 2010.
248. Flaig TW, Glode M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, Su LJ, Li Y, Harrison G, Agarwal R,
Crawford ED, Lucia MS, Pollak M. A study of high-dose oral silybin-phytosome followed by
prostatectomy in patients with localized prostate cancer. Prostate 70: 848-55, 2010.
249. Gill JK, Wilkens LR, Pollak MN, Stanczyk FZ, Kolonel LN. Androgens, growth factors, and risk of prostate
cancer: the multiethnic cohort. Prostate 70: 906-15, 2010.
37
250. Neuhouser ML, Till C, Kristal A, Goodman P, Hoque A, Platz EA, Hsing AW, Albanes D, Parnes HL, Pollak
M. Finasteride modifies the relation between serum c-peptide and prostate cancer risk: results from the
Prostate Cancer Prevention Trial. Cancer Prev Res (Phila Pa) 3: 279-89, 2010.
251. *Blouin MJ, Zhao Y, Zakikhani M, Algire C, Piura E, Pollak M. Loss of function of PTEN alters the
relationship between glucose concentration and cell proliferation, increases glycolysis, and sensitizes
cells to 2-deoxyglucose. Cancer Lett 298: 246-53, 2010.
252. *Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M. Metformin blocks the stimulative effect of a
high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty
acid synthase. Endocr Relat Cancer 17: 351-60, 2010.
253. Pollak M, Russell-Jones D. Insulin analogues and cancer risk: cause for concern or cause célèbre? Int J
Clin Pract 64: 628-36.2010.
254. Okereke OI, Kurth T, Pollak MN, Gaziano JM, Grodstein F. Fasting plasma insulin, c-peptide and
cognitive change in older men without diabetes: results from the Physicians’ Health Study II.
Neuroepidemiology 34: 200-7, 2010.
255. *Mireuta M, Darnel A, Pollak M. IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR
pathway through Sp1-induced increase in transcription. Growth Factors 28: 243-55, 2010.
256. Schumacher FR, Cheng I, Freedman ML, Mucci L, Allen NE, Pollak MN, Hayes RB, Stram DO, Canzian F,
Henderson BE, Hunter DJ, Virtamo J, Manjer J, Gaziano JM, Kolone LN, Tjonneland A, Albanes D, Calle EE,
Giovannucci E, Crawford ED, Haiman CA, Kraft P, Willett WC, Thun MJ, Le Marchand L, Kaaks R, Feigelson
HS, Bueno-de-Mesquita HB, Palli D, Riboli E, Lund E, Amiano P, Andriole G, Dunning AM, Trichopoulos D,
Stampfer MJ, Key TJ, Ma J. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic
variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians.
Human Mol Genet 19: 3089-101, 2010.
257. Pollak M. Beyond steroid hormones: the new cancer endocrinology. Lancet Oncol 11: 501-2, 2010.
258. Major JM, Pollak MN, Snyder K, Virtamo J, Albanes D. Insulin-like growth factors and risk of kidney
cancer in men. Br J Cancer 103: 132-5, 2010.
259. *Inoue T, Zakikhani M, David S, Algire C, Blouin MJ, Pollak M. Effects of castration on insulin levels and
glucose tolerance in the mouse differ from those in man. Prostate 70: 1628-35, 2010.
260. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner
JG, Yee D. Diabetes and cancer: a consensus report. CA Cancer J Clin 60: 207-21, 2010.
261. Hou M, Venier N, Sugar L, Musquera M, Pollak M, Kiss A, Fleshner N, Klotz L, Venkateswaran V.
Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet. BiochemBiophys
Res Commun 397: 537-42, 2010.
262. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner
JG, Yee D. Diabetes and cancer: a consensus report. Diabetes Care 33: 1674-85, 2010.
263. Canzian F, Cox DG, Setiawan VW, Stram DO, Ziegler RG, Dossus L, Beckmann L, Blanche H, Barricarte A,
Berg CD, Bingham S, Buring J, Buys SS, Calle EE, Chanock SJ, Clavel-Chapelon F, Delancey JO, Diver WR,
38
Dorronsoro M, Haiman CA, Hallmans G, Hankinson SE, Hunter DJ, Husing A, Isaacs C, Khaw KT, Kolonel
LN, Kraft P, Le Marchand L, Lund E, Overvad K, Panico S, Peeters PH, Pollak M, Thun MJ, Tjonneland A,
Trichopoulous D, Tumino R, Yeager M, Hoover RN, Riboli E, Thomas G, Henderson BE, Kaaks R, Feigelson
HS. Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and
insulin-like growth factor-I metabolism and breast cancer risk in the NCI Breast and Prostate Cancer
Cohort Consortium. Hum Mol Genet 19: 3873-84, 2010.
264. Douglas JB, Silverman DT, Pollak MN, Tao Y, Soliman AS, Stolzenberg-Solomon RZ. Serum IGF-I, IGF-II,
IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and
ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 19: 2298-306, 2010.
265. Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, Petroulakis E, Robichaud N, Pollak
M, Gaboury LA, Pandolfi PP, Saad F, Sonenberg N. eIF4E phosphorylation promotes tumorigenesis and is
associated with prostate cancer progression. Proc Natl Acad Sci USA 107: 14134-9, 2010.
266. Johnson JA, Pollak M. Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes.
Diabetologia 53: 2086-8, 2010.
267. Major JM, Stolzenberg-Solomon RZ, Pollak MN, Snyder K, Virtamo J, Albanes D. Insulin-like growth
factors and liver cancer risk in male smokers. Br J Cancer 103: 1089-92, 2010.
268. Thomas JA 2nd, Antonelli JA, Lloyd JC, Masko EM, Poulton SH, Phillips TE, Pollak M, Freedland SJ. Effect
of intermittent fasting on prostate cancer tumor growth in a mouse model. Prostate Cancer Prostatic Dis
13: 350-5, 2010.
269. Grimaldi-Bensouda L, Marty M, Pollak M, Cameron D, Riddle M, Charbonnel B, Barnett AH, Boffetta P,
Boivin JF, Evans M, Rossignol M, Benichou J, Abenhaim L; ISICA group. The international study of insulin
and cancer. Lancet 376: 769-70, 2010.
270. Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev
Res (Phila) 3: 1060-5, 2010.
271. Potratz JC, Saunders DN, Wai DH, Ng TL, McKinney SE, Carboni JM, Gottardis MM, Triche TJ, Jurgens H,
Pollak MN, Aparicio SA, Sorensen PH. Synthetic lethality screens reveal RPS6 and MST1R as modifiers of
insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas. Cancer Res 70: 8770-81,
2010.
2011
272. Bordeleau L, Lipscombe L, Lubinski J, Ghadirian P, Foulkes WD, Neuhausen S, Ainsworth P, Pollak M,
Sun P, Narod SA; the Hereditary Breast Cancer Clinical Study Group. Diabetes and breast cancer among
women with BRCA1 and BRCA2 mutations. Cancer 117: 1812-18, 2011.
273. *Algire C, Amrein L, Bazile M, David S, Zakikhani M, Pollak M. Diet and tumor LKB1 expression interact
to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene 30: 1174-82, 2011.
274. Takahara K, Tearle H, Ghaffari M, Gleave ME, Pollak M, Cox ME. Human prostate cancer xenografts in
lit/lit mice exhibit reduced growth and androgen-independent progression. Prostate 71: 525-37, 2011.
39
275. Tognon CE, Somasiri AM, Evdokimova VE, Trigo G, Uy EE, Melnyk N, Carboni JM, Gottardis MM,
Roskelley CD, Pollak M, Sorensen PH. ETV6-NTRK3 mediated breast epithelial cell transformation is
blocked by targeting the IGF1R signalling pathway. Cancer Res 71: 1060-70, 2011.
276. Azoulay L, Dell’aniello S, Gagnon, Pollak MN, Suissa S. Metformin and the incidence of prostate cancer
in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev 20: 337-44, 2011.
277. Douglas JB, Silverman DT, Weinstein SJ, Graubard BI, Pollak MN, Tao Y, Jarmo V, Albanes D,
Stolzenberg-Solomon R. Serum C-reactive protein and risk of pancreatic cancer in two nested, casecontrol studies. Cancer Epidemiol Biomarkers Prev 20: 359-69, 2011.
278. Gualberto A, Hixon ML, Karp DD, Li D, Green S, Dolled-Filhart M, Paz-Ares LG, Novello S, Blakely J,
Langer CJ, Pollak MN. Pre-treatment levels of circulating free IGF-I identify NSCLC patients who derive
clinical benefit from figitumumab. Br J Cancer 104: 68-74, 2011.
279. Kaplan RC, Petersen AK, Chen MH, Teumer A, Glazer N, Doring A, Lam CS, Friedrich N, Newman A,
Muller M, Yang Q, Homuth G, Cappola A, Klopp N, Smith H, Ernst F, Psaty BM, Wichmann HE, Sawyer DB,
Biffar R, Rotter JI, Gieger C, Sullivan LS, Volzke H, Rice K, Spyroglou A, Kroemer HK, Chen YD,
Manalopoulou J, Nauck M, Strickler HD, Goodarzi MO, Reincke M, Pollak MN, Bidlingmaier M, Vasan RS,
Wallaschofski H. A genome-wide association study identifies novel loci associated with circulating IGF-I
and IGFBP-3. Hum Mol Genet 20: 1241-51, 2011.
280. Nimptsch K, Platz EA, Pollak MN, Kenfield SA, Stampfer MJ, Willett WC, Giovannucci E. Plasma insulinlike growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals
Follow-up Study 1993-2004. Int J Cancer 128: 660-7, 2011.
281. Ng K, Sargent DJ, Goldberg RM, Meyerhardt JA, Green EM, Pitot HC, Hollis BW, Pollak MN, Fuchs CS.
Vitamin D status in patients with stage IV colorectal cancer: Finding from intergroup trial N9741. J Clin
Oncol 29: 1599-606, 2011.
282. Mireuta M, Hancock MA, Pollak M. Binding between insulin-like growth factor 1 and insulin-like
growth factor binding protein 3 is not influenced by glucose or 2-deoxy-D-glucose. J Biol Chem. 2011 Mar
9. Epub ahead of print.
283. Yasmeen A, Beauchamp MC, Piura E, Segal E, Pollak M, Gotlieb WH. Induction of apoptosis by
metformin in epithelial ovarian cancer: Involvment of the Bcl-2 family proteins. Gynecol Oncol. 2011 Mar
7. Epub ahead of print.
Book Chapters, Letters, Serials
1. Pollak M. Epidermal growth factor receptors and breast cancer. (letter) Lancet. 2: 562, 1987.
2. Pollak M. Recombinant GM-CSF in myelosuppression of chemotherapy. (letter) New England Journal of
Medicine. 320: 253-4, 1989.
3. Pollak M. Review Bias. (letter) New England Journal of Medicine. 322: 638, 1989.
4. Pollak M. Therapeutic Implications of Recent Growth Factor Research. in High Risk Breast Cancer, Ragaz J
(ed), Springer Verlag, New York, 1991.
40
5. Pollak M. Timing of surgery in breast cancer. (letter) Lancet. 337: 1603-4, 1991.
6. Pollak M. Reference for patients: valuable or misguided? (book review of: Everyone’s Guide to Cancer
Therapy Dollinger M.) J Can Med Assoc. 147: 213-4, 1992.
7. Pollak M. Effects of adjuvant tamoxifen therapy on growth hormone and IGF-1 physiology. in Salmon S.
(ed.) Adjuvant Therapy of Cancer VII Lipincott, Philadelphia, 43-55, 1993.
8. Arbour L, Narod S, Glendon G, Pollak M., Seymour R, Miner L, Leung P. In vitro fertilization and family
history of breast cancer. (letter) Lancet. 344: 610-1, 1994.
9. Pollak M. Potential impact of genetic testing on cancer prevention trials, using breast cancer as an example.
(letter) J Natl Cancer Inst. 87: 1557-8, 1995.
10. Pollak M. Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the
upper aerodigestive tract. (letter) J Natl Cancer Inst. 87: 458, 1995.
11. Pollak M. Reversal by transferrin of growth-inhibitory effect of suramin on hormone-refractory human
prostate cancer cells. (letter) J Natl Cancer Inst. 87: 608-9, 1995.
12. Pollak M. Enhancement of the antineoplastic effects of tamoxifen by somatostatin analogues. in Kellen J.
(ed.) Tamoxifen: Beyond the Antiestrogen Birkhauser, Boston, 359-68, 1996.
13. Pollak M. Hormonal therapies for breast cancer. Current Oncology. 3: s46-s52, 1996.
14. Pollak M. The potential role of somatostatin analogues in the management of breast cancer. Peptide
Therapy Reviews. 8: 1-13, 1996.
15. Pollak M, Ingle J, Suman V, Kugler J. Rationale for combined antiestrogen-somatostatin analogue therapy
of breast cancer. in Salmon S. (ed.) Adjuvant Therapy of Cancer VIII Lipincott, Philadelphia, 145-52, 1997.
16. Pollak M. Cancer controversy. Nature. 392: 752, 1998.
17. Ma J, Giovannucci E, Pollak M, Stampfer M. Prospective study of colorectal cancer risk in men and plasma
levels of insulin-like growth factor (IGF)-I and IGF-binding protein 3. (letter) J Natl Cancer Inst. 91: 2051-2,
1999.
18. Pollak M. American Society for Clinical Oncology: Online continuing medical education segment. Published
on Web. www.conference-cast.com/ASCO, 1999.
19. Pollak, M. IGF-I, IGFBP-3 and Cancer Risk: An Update. (letter) Topical Endocrinology Suppl. 7: 18-9, 2000.
20. Pollak M, Besser M, Cohen P, Rosenfeld R. Overview: First International Workshop on Growth Hormone,
Insulin-like Growth Factors and Neoplasia. Growth Horm IGF Res. 10 Suppl A: 1-3, 2000.
21. Pollak M. Insulin-like growth factor physiology and neoplasia. Growth Horm IGF Res. 10 Suppl A: 6-7, 2000.
22. Byrne C, Hankinson S, Pollak M, Willett W, Colditz G, Speizer F. Insulin-like growth factors and
mammographic density. Growth Horm IGF Res. 10 Suppl A: 24-5, 2000.
41
23. Ma J, Pollak M, Giovannucci E, Chan J, Tao Y, Hennekens C, Stampfer M. A prospective study of plasma
levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3, and colorectal cancer risk among men.
Growth Horm IGF Res. 10 Suppl A: 28-9, 2000.
24. Giovannucci E, Pollak M, Platz E, Willett W, Stampfer M, Majeed N, Colditz G, Speizer F, Hankinson S.
Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and the risk of colorectal adenoma and cancer in the
Nurses' Health Study. Growth Horm IGF Res. 10 Suppl A: 30-1, 2000.
25. Chan J, Stampfer M, Giovannucci E, Ma J, Pollak M. Insulin-like growth factor I (IGF-I), IGF-binding protein-3
and prostate cancer risk: epidemiological studies. Growth Horm IGF Res. 10 Suppl A: 32-3, 2000.
26. Ma J, Stampfer M, Pollak M. Prospective study of colorectal cancer risk in men and plasma levels of
insulin-like growth factor (IGF)-I and IGF- binding protein-3. (letter) J Natl Cancer Inst. 92: 1949, 2000.
27. Pollak M. Serum IGF-I, IGF-II, and IGFBP-3 Levels and Cancer Risk. Published on Web.
www.dslabs.com/dslabs/1998_sabm.htm, 2000.
28. Pollak M. How do anti-oestrogens work? in Tobias J, Houghton J, and Henderson I. (eds.) Breast Cancer:
New Horizons in Research and Treatment Oxford University Press, New York, 2001.
29. Pollak M. IGF-I, Insulin and Cancer Risk: Linking the Biology and the Epidemiology. In LeRoith D, Zumkeller
W, Baxter R. (eds.) Insulin-Like Growth Factors (chapter 20) Eurekah.com. , 2003.
30. Narasimhadevara R, Pollak MN, Foulkes WD. Italian randomized trial among women with hysterectomy:
tamoxifen and hormone-dependent breast cancer in high-risk women. (letter) J Natl Cancer Inst. 95: 917-9,
2003.
31. Pollak M. Insulin-like growth factors and neoplasia. Novartis Found Symp. 262: 84-8, 98-107, 265-8, 2004.
32. Pollak M. Individualizing Interventions for Cancer Prevention. in Senn H-J, Morant R.(eds.) Recent Results
in Cancer Research 166: 63-70, 2005.
INVITED LECTURES
(Only a subset of presentations is listed.)
1984
Memorial University, Newfoundland, November
Grand Medical Rounds
1985
Jewish General Hospital, Montreal, annually to present
Grand Medical Rounds
1986
Montreal General Hospital, Montreal, November
42
Oncology Rounds
Lady Davis Institute, Montreal, December
Molecular Biology Seminar
1987
Royal Victoria Hospital, Montreal, February
Interdisciplinary Oncology Rounds
McGill Cancer Center, Montreal, February
Research Seminar
Department of Medicine, Jewish General Hospital, Montreal, February
Staff Research Seminar
Notre-Dame Hospital, Montreal, February
Interhospital Oncology Rounds
Bristol Myers Company, Wallingford, CT, November
Novel hormonal cancer therapies
Lady Davis Institute for Medical Research, Montreal, December
Staff Seminar
1988
Jewish General Hospital, Montreal, January
Surgical Grand Rounds
NSABP-NCI Annual Meeting, Tampa, January
Plenary Session, Incorporating basic science investigations into clinical trials
Sandoz Canada, Dorval, Quebec, June
Invited Speaker
Montreal General Hospital, Montreal, June
Grand Medical Rounds
Somatostatin analogues in cancer therapy workshop, Sandoz Pharma, Basle, Switzerland, October
Invited Participant
1989
First Annual European Winter Oncology Conference, Crans-Montana, Switzerland, January
Mechanisms of action of somatostatin analogues as antineoplastic agents
National Cancer Institute of Canada Clinical Trials Group Meeting, Montreal, April
Breast Cancer Session, Innovative Hormonal Treatments for Breast Cancer
43
Mamonides Hospital, Montreal, October
Grand Rounds, Breast Cancer
1990
Montreal General Hospital, Montreal, January
Oncology Rounds
Jewish General Hospital, Montreal, April
Family Practice Rounds, The role of the primary care physician in oncology care
NCIC Clinical Trials Group Meeting, Toronto, April
IGF-I and sarcomas
NCIC Pharmacists’ Meeting, Toronto, April
Prostate cancer: treatment strategies
Reunion Interhospitaliere en Oncologie Medicale, Montreal, May
Invited Speaker
Lake Ontario Metastasis Group Meeting, Hamilton, Ontario, June
Invited Speaker
Princess Margaret Hospital and Bayview Regional Cancer Center, Toronto, October
Invited Speaker
NCIC Terry Fox sarcoma conference, London, Ontario, December
Invited Participant
1991
2nd international symposium on IGF-I, San Francisco, January
Plenary Session
Royal Marsden Hospital, London, UK, February
Invited Speaker
Jewish General Hospital, Montreal, March
Grand Medical Rounds
McGill University, Department of Clinical Biochemistry, Montreal, March
Research Seminar
Princess Margaret Hospital, Toronto, April
Grand Rounds, IGF-I role in sarcomas
Somatostatin–State of the Art Symposium, Monte Carlo, October
Plenary Session
McGill Cancer Center, Montreal, November
44
Somatomedins in cancer
Department of Endocrinology, Montreal Children’s Hospital, Montreal, November
In vitro studies concerning responsivity of human cancers to somatomedins
University of Ottawa, Ottawa, November
IGF-I in breast cancer
1992
Hope and Cope Members Meeting, Montreal, January
Non-cytotoxic cancer treatments
Queens University, Kingston, Ontario, February
Somatomedins and cancer - opportunities for basic science components within clinical trials
NCIC Breast Cancer Meeting, Niagara Falls, March
IGF-I in breast cancer
University of Toronto Breast Cancer Conference, Toronto, April
Effect of tamoxifen on IGF-I physiology
NCIC Clinical Trials Conference, Toronto, April
Somatostatin analogues as novel agents in breast cancer
IGF Workshop, Nice, France, August
Invited Speaker
NCI-NIH, Bethesda, MD, USA, September
IGF and Sarcomas
Reichmann Research Institute, Sunnybrook Hospital, Toronto, October
Invited Speaker
Jewish General Hospital, Montreal, December
New Developments in Hormonal Treatment of Cancer
NSABP Biological Markers Committee Meeting, Hilton Head, December
IGF-1 as potential intermediate end point in prevention studies
CALGB Breast Committee Meeting, Washington, DC, December
Somatostatin analogues as potential agents for breast cancer
1993
NCIC symposium on cancer research, Laval University, Quebec City, January
Invited Speaker
Tucson Adjuvant Therapy Conference, Tucson, March
Plenary Session, Invited Speaker
45
Institute Henry Beaufort, Washington, DC, March
Invited Speaker
Vanderbilt University, Nashville, April
Grand Rounds and Faculty Club lectures Visiting Professor
NSABP protocol design committee meeting, Pittsburgh, June
Somatostatin-antiestrogen interactions: preclinical and early clinical data
Sandoz Research Institute, East Hanover, NJ, July
Somatostatin-antiestrogen synergy
NSABP Group Meeting, Chicago, October
Tamoxifen-somatostatin interactions
Mount Sinai Hospital Chemotherapy Foundation, New York City, November
Newly described mechanisms of action of tamoxifen
Sandoz Research Institute, East Hanover, NJ, November
Novel oncological applications of hypothalamic releasing factor analogues
American Health Foundation, New York City, December
Tamoxifen effects on IGF-I physiology: relationships to efficacy and toxicity of the drug
1994
International IGF meeting, Sydney, Australia, January
Plenary Lecture, IGFBP-4 linkage to hereditary breast cancer
(presentation delegated to a colleague)
Sandoz Research Center, Basle, Switzerland, March
Somatostatin analogues and neoplasia
Lancet Breast Cancer Conference, Brussels, Belgium, April
Plenary session, IGF system of mitogens and breast cancer
Tamoxifen-Sandostatin multinational trial meetings, London, England and Montreal, June
Rationale for combining antiestrogens and somatostatin analogues in breast cancer treatment
Karolinska Institute, Stockholm, Sweden, June
Academic Visitor
(1) A novel tumor suppressor gene on chromosome 1p35
(2) IGF binding proteins in breast cancer
NSABP group meeting, Tampa, June
Plenary session speaker, Rationale for clinical trials involving somatostatin analogues combined with
antiestrogens in the treatment of breast cancer
1995
46
Hadassah Hospital, Hebrew University, Jerusalem, Israel, January
Visiting Professor and lecturer, IGF system of mitogens and neoplasia
Somatostatin Symposium, Eilat, Israel, January
Oncological applications of somatostatin analogues
NSABP protocol design committee meeting, Washington, DC, January
Rationale for clinical trials involving somatostatin analogues combined with antiestrogens in the treatment of
breast cancer
5th Breast Cancer Adjuvant Therapy Symposium, St. Gallen, Switzerland, March
Growth factors and neoplasia: recent progress
Hamilton Regional Cancer Center, Hamilton, Ontario, April
Oncology Grand Rounds, Pathophysiology of somatomedins in neoplasia
National Cancer Institute of Canada Clinical Trials Group Meeting, Toronto, May
Proposed tamoxifen-octreotide adjuvant trial design
Human Genome Sciences, Inc., Washington, DC, August
Relating gene discovery to physiology: the case of MDGI
Octreotide Clinical Research Meeting, Sandoz Research Institute, Frankfurt, September
Breast cancer and octreotide
Nottingham Breast Cancer Meeting, Nottingham, UK, September
Discussion group participant, IGF-related serum markers in breast cancer
International symposium on IGF binding proteins, Tubingen, Germany, October
Invited Plenary Speaker, IGFBPs and antiestrogen action
Harvard School of Public Health, Boston, October
IGF-I, nutrition, body size, and neoplasms of colon and breast: new relationships
Chemotherapy Foundation Symposium XIII, New York City, November
Somatostatin analogues: mechanisms of action as antineoplastics
European Federation of Endocrine Societies Meeting, Sorrento, Italy, November
Somatostatin analogs: basic and clinical perspectives
Montreal General Hospital Research Institute Seminar Series, Montreal, December
IGFs in breast cancer pathogenesis
1996
Royal Victoria Hospital, Montreal, January
Medical Grand Rounds, New directions in cancer endocrinology
Orion Pharmos, Turku, Finland, January
47
Antiestrogen action: involvement of insulin-like growth factors
Site review of NSABP by NCI (USA), Pittsburgh, February
Invited Speaker
NSABP general meeting, Orlando, March
Invited Speaker
8th International Conference on the adjuvant therapy, Scottsdale, Arizona, March
Plenary session, Enhancement of tamoxifen-induced suppression of serum IGF-1 levels in metastatic breast
cancer patients by co-administration of the somatostatin analogue octreotide
McGill Continuing Medical Education Program, Montreal, March
47th Refresher Course for Family Physicians
Controversies surrounding breast cancer genetic testing
NCIC Clinical Trials Group Meeting, Toronto, April
The MA14 Trial
International Association of Pancreatology, Mannheim, Germany, June
Invited Speaker (presentation delegated to a colleague)
Scherring-Plough Antiestrogen Symposium, Bermuda, July
Invited Speaker
National Cancer Institute/NIH (USA), Bethesda, MD, October
IGFs: biological and epidemiological evidence for a relationship to breast cancer
Yale University, New Haven, CT, November
Plenary speaker, Biology and clinical relevance of somatostatin receptor
University of British Columbia, Vancouver, December
Visiting Professor
(1) IGF binding proteins in post-lactational involution and antiestrogen action.
(2) Novel non-cytotoxic approaches to sarcoma treatment
(3) Mammary derived growth inhibitor: role in breast differentiation and pathophysiology in breast cancer
(4) Somatostatin-antiestrogen interactions: the MA14 trial
1997
University of Pittsburgh, Pittsburgh, March
Prospects for non-cytotoxic therapy of pancreatic cancer
Biochem Pharma, Montreal, April
Novel natural source metalloproteinase inhibitors.
McGill Endocrinology Department Retreat, Montreal, May
Invited Speaker
Ron Buick Memorial Symposium, University of Toronto, Toronto, May
48
Translational research: case studies in Oncology
European Endocrine Society Meeting, Sorrento, Italy, June
Mechanism of action of noncytotoxic anticancer therapies: octreotide
McGill Oncology Department Beer “Chalk Talk”, Montreal, September
IGFs and neoplasia—new data
Scripps Clinic, University of California, San Diego, October
Invited Speaker
World Insulin-like growth factor Congress, Tokyo, October
Invited Speaker
“Tamoxifen and the Uterus” symposium, Brussels, December
Invited Speaker
1998
Bayview Regional Cancer Center, Toronto, January
A novel risk factor for breast and prostate cancer
6th International Conference on Adjuvant therapy, St Gallen, Switzerland, February
Invited Speaker
Annual Meeting of the American Association for Cancer Research, “Molecular basis of cancer susceptibility”
symposium, New Orleans, March
Invited Speaker
Novartis Pharma, meeting of experts on prostate cancer, New Orleans, March
Invited Speaker
Merck Pharma, Rahway, New Jersey, April
Invited Speaker
Cancer Center of New Jersey, New Brunswick, New Jersey, April
Invited Speaker
Novartis Pharmaceuticals, Basle, Switzerland, April
External Experts consultative session regarding somatostatin analogues
Cancer Prevention Lecture Series, University of Toronto, Toronto, April
Invited Speaker
National Cancer Institute of Canada Annual Meeting, Montreal, May
Invited Speaker
Axys Pharma, San Francisco, May
Invited Speaker
49
Annual Meeting of the American Society of Clinical Oncology, Los Angeles, May
“Issues in early breast cancer” symposium
Invited Speaker
Cancer Control Agency of British Columbia, Vancouver, June
Invited Speaker
Montreal Children’s Hospital, Montreal, June
IGFs and cancer risk
The Jackson Laboratory, Bar Harbor, Maine, August
Invited Speaker
Cadus Pharmaceuticals, New York, September
Invited Speaker
CAPCURE Annual Meeting, Lake Tahoe, September
Invited Participant
DSL IGF World Experts Symposium, Oregon, September
Invited Speaker
McGill University, Department of Anatomy, Montreal, September
Rates of epithelial cell turnover and IGF-1
Royal College of Physicians and Surgeons Annual Meeting, Toronto, September
Invited Speaker (unable to attend)
University of Toronto Prostate Cancer Symposium, Toronto, October
Invited Speaker
Residents lecture series–McGill University, Montreal, October
Prostate Cancer
Danna Farber Cancer Center, Harvard University, Boston, October
Invited Speaker
Axys Pharmaceuticals, San Diego, December
Invited Speaker
KIGS National Meeting, Laguna Niguel, California, December
Plenary Session speaker, The GH-IGF axis and neoplasia
1999
Zeneca Pharma, Montreal, March
New aspects of gonadal steroid ablation therapy
Sunnybrook-Women’s College Hospital, Toronto, March
Oncology Grand Rounds, Gonadal steroid ablation therapy
50
Chemoprevention Branch, National Cancer Institute USA, Bethseda, MD, March
Invited Speaker
Ipsen Biotech, Boston, March
Drug development opportunities related to advances in growth factor research
Pediatric brain tumor endocrinology group, San Francisco, April
Invited Speaker
British Endocrine Societies, Annual Meeting, Bournemouth, UK, April
Plenary session, Invited Speaker
NCIC Clinical Trials Group, Toronto, April
MA14 Clinical Trial: Progress
Senate Committee Hearing, Government of Canada, Ottawa, April
Expert witness regarding bovine somatropin
Department of Endocrinology, Jewish General Hospital, Montreal, May
Cancer Endocrinology
Biochem Pharma, Montreal, May
Novel molecular targets for antineoplastic therapy
Late breaking research AACR session, Philadelphia, April
Selected presentation, Relationship of colorectal cancer risk to serum IGF-I and IGFBP-3 levels
ASCO Annual Meeting, Atlanta, May
IGF-I physiology and colorectal cancer risk
Harvard University Center for Cancer Prevention, Boston, June
Workshop on IGF and cancer risk, Invited Speaker
Lilly Global Medical Conference, Indianapolis, June
Prospects for pharmacological reduction of cancer risk
National Meeting of Canadian Breast Cancer Research Initiative, Toronto, June
IGF physiology: clues for new approaches to breast cancer research and treatment
Canadian Urological Society Meeting, London, Ontario, June
IGF physiology: relevance to prostate cancer biology
Institut Ipsen-Beaufort, Paris, France, July
Somatostatin and neoplasia
Chemoprevention Branch Prostate Cancer Prevention Symposium, National Cancer Institute, Washington, DC,
August
Invited Speaker (presentation delegated to a colleague)
51
NSABP clinical trials group, Toronto, August
B29 trial: update regarding rationale and experience to date
Pharmacia Upjohn Growth Hormone Congress, Boston, October
IGF physiology and cancer risk
International Workshop on growth hormone, Insulin-like growth factors and neoplasia, Boston, October
Invited Speaker
International Symposium on IGFs, Brighton, UK, October
Invited Speaker
UICC Cancer Prevention Symposium, Beijing, China, October
Invited Speaker (presentation delegated to a colleague)
AACR Meeting on “Biology of cancer risk”, Bal Harbor, Florida, October
IGF biology and cancer prevention
CAPCURE 6th annual Scientific Retreat, Lake Tahoe, Nevada, October
Invited Delegate
Princess Margaret Hospital, Toronto, December
IGF physiology and breast cancer: basic and translational aspects
2000
UICC Prostate Cancer Symposium, Eilat, Israel, January
Peptide growth factors: Relevance to prostate cancer
Tumor Prevention and Genetics 2000 Symposium, St Gallen, Switzerland, February
Invited Speaker
M.D. Anderson Hospital, Houston, Texas, March
Invited Speaker
National Cancer Institute of Canada Clinical Trials Meeting, Toronto, April
Invited Speaker
Bristol Myers-Squibb, Pharma, New Jersey, April
Invited Speaker
19th International Meeting on Endocrinology and Development, Sorrento, Italy, May
Invited Speaker
3rd International Workshop of the Growth Hormone Research Society, Washington, D.C., May
Invited Delegate
“Hormonal Carcinogenesis” International Conference, St. Petersburg, Russia, May
Invited Speaker
52
Endocrine Society Annual Meeting, Plenary Session, Toronto, June
Invited Speaker
International Symposium on IGFs and Cancer, Halle, Germany, September
Invited Speaker
CAPCURE 7th annual Scientific Retreat, Lake Tahoe, Nevada, September
Invited Delegate
International Endocrine Congress, Plenary Session, Sydney, Australia, October
Invited Speaker
NCI (USA) Symposium on physical activity and cancer risk, Dallas, Texas, November
Invited Speaker
2001
Millennium Pharmaceuticals, Boston, February
Invited Speaker
Mc Gill University, Centre for Clinical Epidemiology and Community Studies, Montreal, February
IGF and Cancer risk
Federation of General Surgeons of Quebec, May
Invited Speaker
Axys Pharmaceuticals, South San Francisco, June
Invited Speaker
Astra-Zeneca IMPACT meeting, Manoir Richelieu, Quebec, June
Invited Speaker
Fred Hutchinson Comprehensive Cancer Center, Seattle, June
IGFs: Potential Relevance to cancer prevention & treatment
8th Annual Meeting of CAPCURE. Lake Tahoe, September
Invited Speaker
“A mechanism of androgen-independence related to IGF signaling in prostate cancer.”
McGill University Health Science Center, Montreal, December
Invited Speaker, Urology Department, “Insulin-like growth factors and prostate cancer.”
2002
University Health Network-Princess Margaret Hospital, Toronto, January
Oncology Grand Rounds, “Insulin-like growth factors: relevance to prostate cancer.”
Diagnostic Systems Limited, Houston, Texas, January
Invited Speaker, “Methods in IGF measurements.”
53
Telik Inc., San Francisco, California, January
Invited Speaker, “IGF signaling in neoplasia: opportunities for drug development.”
NCIC Clinical trial group, Toronto, February
“Future of Breast Cancer Treatment” Workshop, “Herceptin resistance and IGF signaling.”
Albert Einstein University, New York City, February
Invited Speaker, “Endocrine epidemiology of IGF’s.”
Prostate Cancer Prevention Trial Management Committee, South West Oncology Group,
Invited Speaker
San Antonio, Texas, February
“Prostate Cancer Prevention: New Opportunities.”
EORTC European Breast Cancer Congress, Barcelona, Spain, March
Invited Speaker, “Biology underlying breast cancer prevention strategies”
EORTC European Breast Cancer Congress, Barcelona, Spain, March
Oral Presentation, “MA14 Adjuvant Breast Cancer Treatment Trial”
Gordon Conference on “New frontiers in cancer detection and diagnosis”, Ventura Beach, California, March
Invited Speaker, “Host factors influencing rate of carcinogenesis: the case of insulin-like growth factors”
AACR Annual meeting, San Francisco, April
Invited Speaker, “Daybreak-Meet-the-Expert-Session” IGF’s and Neoplasia
Novartis Opinion Leaders Meeting, Switzerland, June
Invited Participant
Astra-Zeneca Opinion Leaders Meeting, New York City, July
Invited Participant
16th World Congress of Epidemiology, Montreal, August
Invited Speaker
CaPCURE Annual Meeting, Washington D.C., September
Invited Participant
Canadian Endocrinology Society Annual Meeting, Vancouver, October
“New Frontiers in Cancer Endocrinology”
Invited Speaker, “Hormones and Cancer”
AACR Special Meeting on Cancer Prevention, Boston, October
Invited Speaker
International Symposium on IGF binding proteins, Tubingen, Germany, October
Invited Speaker
54
Chagnon Foundaton, International Cancer Prevention Symposium, Montreal, November
Speaker and Chairman, Scientific Committee
Canadian Breast Cancer Research Initiative, Scientific Retreat, Toronto, November
Invited Participant
2003
Procyon Biopharma, Montreal, January
Invited Speaker
“Novel Therapeutic Targets” Symposium, Monte Carlo, February
Invited Speaker
International Agency for Research on Cancer (IARC), Lyon, February
Invited Speaker
Gordon Conference on “IGFs in Health and Disease”, Ventura Beach, March
Invited Speaker
Prostate Cancer Prevention Trial, Translational Science Project, San Diego, April
Invited Speaker
Novartis Pharma Global Oncology Advisory Board, New Jersey, April
Invited Speaker
AACR Annual Meeting, Washington D.C., July
Invited Speaker: “Meet-the-Expert” Sunrise Session: Insulin, IGFs, and neoplasia
Epidemiology Department, Johns Hopkins University, August
Invited Speaker
Novartis Foundation Symposium, London, October
Invited Speaker: “Biology of IGF-I: interaction with insulin in health and malignancy”
2004
South West Oncology Group, San Antonio, January
Invited Speaker
Aventis Pharma, Paris, January
Invited Speaker
Merck, Rahaway, New Jersey, January
Invited Speaker
Novartis Pharma, Basel, February
Invited Speaker
St. Gallen Cancer Prevention Meeting, Switzerland, February
55
Invited Speaker and Member of Organizing Committee
American Association for Cancer Research, Orlando, March
Invited Speaker and moderator of a ‘Forum’ on “IGF-I: roles in aging, cancer risk, and cancer treatment”
Scherring Plough Research Institute, New Jersey, September
Invited Speaker
Prostate Cancer Fundation (CAPCURE), Lake Tahoe, October,
Invited Plenary Speaker
Endocrinology Ground Rounds, University of Toronto, Toronto, November
Invited Speaker
2005
Pfizer Research Institute, Groton CT, January
Invited Speaker ‘Targeting the IGF-R and downstream pathways: from lab to clinic’
M.D. Anderson Cancer Center, Huston, TX, January
Invited Speaker ‘Influence of body composition on cancer prognosis: mechanisms’
Gordon Research Conference, “IGFs in Health and Disease”, Ventuna Beach, March
Session Chair
International Symposium on Targeted Cancer Therapies, Amsterdam, March
Invited Speaker
University of Colorado, Denver, Oncology Rounds, March
Invited Speaker
South West Oncology Group, Denver, April
Invited Speaker
Canadian Prostate Cancer Research Network, Vancouver, May
Invited Speaker
Sunnybrooke Hospital, Prostate Cancer Research Center, Toronto, May
Invited Speaker
Astra-Zeneca Advisory Board, Vancouver Island, July
Invited Speaker
Prostate Cancer Foundation (CAPCURE), Phoenix, September
Invited delegate
IGF-I Receptor Targeting Specialist Meeting, Sicily, Italy, November
Invited Speaker
M.I.T. hosted “cohort Consortium” working group, Boston, Novemeber
56
Invited delegate
NCI (USA) Prostate Cancer Biomarkers Workshop, Denver, December
Invited Speaker
2006
3rd Annual European Cancer Prevention Meeting, St. Gallen, Switzerland, February
Program Committee and Invited Speaker
“Keystone Conference” New Molecular insights concerning carcinogenesis and cancer prevention, Colorado,
March
Invited Speaker
‘Nutritional and Metabolic cancer risk factors’, Harvard Medical School, Boston, March
Invited speaker
Cancer Care Ontario Cohort Planning Meeting, Toronto, March
Invited participant
Prostate Cancer Prevention Trial / SWOG Group Meeting, Salt Lake City, April
Invited speaker
Canadian Breast Cancer Research Alliance “Reasons for Hope” Conference, Montreal, May
Invited Plenary speaker
Canadian Prostate Cancer Research Initiative, Biomarkers Workshop, Niagara Falls, May
Invited speaker
Canadian Breast Cancer “Weekend to end breast cancer” workshop, Vancouver, June
Invited Speaker
ASCO meeting, Podium Presentation, Breast Cancer Session, Atlanta, June
Lecture
MD Anderson Cancer Centre, Houston, June
Invited speaker
Harvard University, Dept. of Nutrition, Boston, October
Invited Speaker
Sanofi Aventis, Paris, October
Invited speaker
Prostate Cancer Foundation (USA), Arizona, October
Invited Speaker
Harvard – McGill Milk symposium, Boston, October
Co- Organizor and speaker
57
AACR Cancer Prevention Meeting, Boston, November
Invited Speaker
Department of Endocrinology, University of Toronto, November
Invited Speaker
Department of Endocrinology, UCLA, December
Invited Speaker
2007
Prostate Cancer Foundation of Canada, Hockley Valley, Ontario, January
Invited Speaker
Gordon Research Conference, Ventura beach, California, March
Speaker
Endocrinology Rounds, Royal Victoria Hospital, Montreal, May
Invited speaker
ASCO Annual Meeting, educational session, Los Angeles, June
Invited Speaker
Endocrine Society Annual Meeting, Toronto, June
Invited Speaker
“Weekend to End Breast Cancer” Scientific Symposium, Toronto, July
Invited Speaker
“Molecular Targeting in Oncology” Symposium, Washington DC, August
Invited Speaker
Amgen Pharmaceuticals Retreat, Washington DC, August
Invited Speaker
US Army Prostate Cancer Research Program Symposium, Atlanta, September
Invited Speaker
Canadian Prostate Cancer Foundation Scientific Meeting, Toronto, September
Invited Speaker
Astra Zeneca Pharma, San Francisco, September
Invited Speaker
Antibody Therapy in Oncology, Quebec, September
Invited Speaker
Medical Oncology Rounds, Cancer Control Agency of BC, October
Invited Speaker
58
Amgen Pharma, Thousand Oaks, California, October
Invited Speaker
Abbott Pharmaceuticals, Abbott Park, Chicago, October
Invited Speaker
Prostate Cancer Foundation (Capcure) Annual Scientific Retreat, Lake Tahoe, October
Invited Plenary Speaker
Astra-Zeneca Pharma, Boston, November
Invited Speaker
Pfizer (Endocrinology), Miami, November
Invited lecture to clinical trials group
University Lund, Sweden, November
Invited Speaker and visiting Professor
Bristol Myers Squibb, New York, December
Speaker/organizer, meeting of academic consultants
AACR Cancer Prevention Meeting, Philadelphia, December
Invited Speaker
Annual San Antonio Breast Cancer Symposium, San Antonio, December
Invited Plenary Speaker (audience of 8000)
2008
NCIC Prostate Cancer Alliance, Novel Therapies Symposium, Vancouver, January
Organizing Committee and Speaker
NCIC Clinical Trails Group – Breast and I.N.D. Committees, Toronto, January
Invited participant in clinical trial planning session
ASCO Genito-urinary cancers symposium, San Francisco, February
Invited Plenary speaker (declined)
Pfizer Global Research, New York, February Advisors’ Meeting
Invited Speaker
AACR-NCI Conference on Energetics and Cancer, Washington DC, February
Invited Speaker
University of Toronto, Department of Surgery, Toronto, February
Invited Speaker
3 rd European Cancer Prevention Meeting, St Gallen, Switzerland, March
Invited Plenary Speaker
59
NCI-EORTC “Targeted Therapy in Oncology” Meeting, Washington, March
Invited Plenary Speaker
Canadian Breast Cancer Research Alliance, Reason for Hope Conference, Vancouver, April
Invited Plenary Speaker
Joint United Kingdom – Canadian prostate cancer symposium, Toronto, June
Invited Speaker
Harvard University – Massachusetts General Hospital, Boston, June
Invited Speaker
European Spring Oncology Conference (ESOC-V), Málaga, Spain, June
Invited Speaker
PACRIM Cancer Symposium, Whistler, BC, August
Invited Speaker
ASCO Breast Cancer Symposium, Washington DC, September
Invited Speaker
European Society of Medical Oncology Annual Meeting, Stockholm, September
Invited Speaker
Southern Italian Oncopathology Meeting, University of Calabria, September,
Invited Speaker
NCI Cancer Prevention Branch Symposium, Bethesda, MD, September
Invited Speaker
Weitzman Institute Oncology Research Groups, Israel, October
Invited Speaker
University of Nice / INSERM Cancer Therapeutics symposium, Nice, October
Invited Speaker
International Symposium of Princess Takamatsu Cancer Research Fund, Tokyo, November
Invited Speaker
2009
NIH/NCI Cancer Prevention Symposium, Washington DC, February
Invited Speaker
Gordon Conference ‘Insulin-like growth factors in Health and Disease’, Ventura, California, March
Speaker
NCI-EORTC Targeted therapy meeting, Amsterdam, March,
Invited Speaker
60
UT MD Anderson Symposium on Cellular Energy, Metabolism and Cancer, Houston, April
Invited Speaker
NCIC Clinical Trial Group meeting, Toronto, May
Invited Speaker
Prostate Cancer Prevention Trial – NCI P01 Program, Chicago, May
Invited Speaker
Terry Fox Research Institute Research Symposium, Vancouver, May
Invited Speaker
ASCO (American Society of Clinical Oncology), Orlando, May
Invited Faculty and Speaker
Pituitary Society, Washington, DC, June
Invited Speaker
NCI (USA) Special Conference on Cancer Energetics, Bethesda, MD, July
Invited Speaker
Novo Nordisk, Copenhagen, Denmark, August
Invited speaker
Beckman Corporation – Diagnostic Systems Laboratories, Houston, August
Invited Speaker
Sanofi Aventis
Expert panel on insulin and neoplasia, Providence, Rhode Island, August
Imclone Systems Ltd
Global consensus advisory board regarding targeted therapies, London, UK, October
Invited Speaker
Prostate Cancer Foundation (USA) Scientific Retreat, Lake Tahoe, NV, Sept
Session Chair and Invited Speaker
Klinische Forschergruppe sponsored International meeting on molecular GI cancer treatment, Gottingen
University, Germany, September
Invited Speaker
Prostate Cancer Prevention Trial, External Advisory Board Meeting, Chicago, September
Participant
AACR Symposium on cancer energetics, San Diego, September
Invited Speaker (delegated to student)
Institut de Cancerologie Gustove Roussy, Villejuif (Paris), November
Invited Speaker
61
Spanish National Cancer research Centre-sponsored conference: “Energy of Cancer”, Madrid, November
Speaker
Joint American Cancer Society – American Diabetes Association meeting on cancer, insulin and diabetes,
Atlanta, December
Invited Speaker
2010
AACR special meeting on targeted therapies in lung cancer, San Diego, January
Invited Plenary Speaker
AACR special meeting on protein translation and neoplasia, San Diego, February
Invited Plenary Speaker
Targeted therapies in pulmonary oncology workshop, Santa Monica, CA, February
Invited Speaker
Asian Targeted Therapy Congress, Tokyo, Japan, March
Invited Speaker
International Congress of Endocrinology, Kyoto, Japan, March
Invited Speaker DECLINED
International Symposium on LKB1/AMPK and cancer energetics, Marseilles, May
Invited Speaker
UK Cancer Research Meeting, Edinburgh, Scotland, June
Keynote Speaker
“eurocancer 2010” , Paris, France, June
Invited Speaker
6th annual european spring oncology conference (‘ESCOC-6’) Marbella, Spain, June
Invited Speaker
Australia – Canada Prostate Cancer Foundations joint Symposium, Gold Coast, Australia, August
Invited Speaker and Session Chair
Insulin Receptor Biology Symposium, Genoa, Italy, October
Invited Speaker
Thought leaders in cancer energetics meeting, Banbury Centre, Cold Spring Harbor, NY, October
Invited Speaker
LKB1, AMPK, and Cancer Energetics Symposium, Kyoto, Japan, October
Invited Speaker
National Cancer Institute (INCa) of France sponsored “International forum on cancer research and
treatment”, Assemblee Nationale, Paris, France, November
62
Invited Speaker
AACR Cancer Prevention Meeting, Philadelphia, PA, November
Invited Speaker
“Diabetes and Care”, Paris, France, December
Invited Speaker
Grand Rounds, Department of Medicine, Jewish General Hospital, Montreal, Canada, December
Invited Speaker
2011
Grand Rounds, Department of Gynecology, Jewish General Hospital, Montreal, Canada, January
Invited Speaker
Amgen, Toronto, Canada, January
Invited Speaker
63